Banner

Click on the topic below to view posters

Poster Presentations Session II
POSTER PRESENTATIONS SESSION I - MONDAY, MAY 21, 2007
Poster Display Hours: 9:45AM - 8:00PM

HEALTH CARE USE & POLICY STUDIES

PHP1
MEDICATION SAFETY IN COMMUNITY PHARMACY: IMPACT OF SOCIOTECHNICAL FACTORS ON DISPENSING ERRORS

Parekh A, Szeinbach SL, Seoane-Vazquez E
Ohio
State University, Columbus, OH, USA

PHP2
WASTE OF DRUGS IN TURKEY

Gulmez E1, Malhan S2, Ergun H1, Tulunay FC3

1
Ankara University, Medical School, Ankara, Turkey, 2Baskent University, Faculty of Health Sciences, Ankara, Turkey, 3Medical School of Ankara University, Ankara, Turkey

PHP3
PRESCRIPTION DRUG COST-SHARING AMONG COMMERCIALLY-INSURED CHILDREN AND ADULTS WITH CHRONIC ILLNESS

Gibson TB

Thomson Medstat, Ann Arbor, MI, USA

PHP4
FACTORS INFLUENCING USER CHOICES TO VISIT EITHER GENERAL PRACTITIONERS OR COMMUNITY PHARMACISTS FOR MINOR AILMENTS - A DISCRETE CHOICE EXPERIMENT

Hughes D
1, Myles S2, Longo M2, Lisles C2, Hood K3
1
University of Wales, Bangor, Bangor, UK, 2University of Glamorgan, Pontypridd, UK, 3Cardiff University, Cardiff, UK

PHP5
WILLING TO WAIT: THE INFLUENCE OF PHYSICIAN WAITING TIMES ON SATISFACTION WITH CARE

Anderson RT
1, Balkrishnan R2
1
Wake Forest University School of Medicine, Winston Salem, NC, USA, 2The Ohio State University College of Pharmacy, Columbus, OH, USA

PHP6
CHARACTERISTICS OF PATIENTS RECEIVING PHARMACEUTICAL SAMPLES AND ASSOCIATION BETWEEN SAMPLE USE AND OUT-OF-POCKET PRESCRIPTION COSTS

Alexander GC
, Zhang JX, Basu A
University of Chicago, Chicago, IL, USA

PHP7
GENERIC-NAME PRESCRIPTION AND PERCEIVED QUALITY IN THE DEMAND FOR PHARMACEUTICALS IN ARGENTINA

Maceira DA
, Kurtzbart R
Center for the Study of the State and Society, Buenos Aires, Argentina

PHP8
RACIAL/ETHNIC DISPARITIES IN PRESCRIPTION DRUG UTILIZATION AND OUT-OF-POCKET COSTS

Bhandari A

University
of Maryland, School of Pharmacy, Baltimore, MD, USA

PHP9
THE IMPACT OF MAIL ORDER PHARMACY IN DRUG UTILIZATION AND REIMBURSEMENT IN A LARGE RETIREMENT SYSTEM

Seoane-Vazquez E, Rodriguez-Monguio R, Visaria J

Ohio
State University, Columbus, OH, USA

PHP10
ASSESSING PAYER AND EMPLOYER PERSPECTIVES RELATED TO VALUE IN HEALTH CARE

Bresnahan BW
1, Carlson R1, Garrison LP1, Carpenter G2, Neumann PJ3, Sullivan SD1
1
University of Washington, Seattle, WA, USA, 2WorkWell Systems, Inc, Aliso Viejo, CA, USA, 3Tufts-New England Medical Center, Boston, MA, USA

PHP11
THE VOLUNTARY INCENTIVE STRUCTURE OF PEDIATRIC EXCLUSIVITY AND ITS IMPACTS ON PHARMACEUTICAL INDUSTRY BEHAVIOR AND GENERIC DRUG ENTRIES

Rhee J

UCLA, Los Angeles, CA, USA

PHP12
DIFFERENCES IN CHRONIC DISEASE CARE OF PRE_MEDICARE INDIVIDUALS BETWEEN METROPOLITAN AND NON-METROPOLITAN SETTINGS

Raofi S

Centers for Disease Control and Prevention, Hyattsville, MD, USA

PHP13
THE TRENDS IN PRESCRIBING OF HERBAL MEDICINES IN AMBULATORY SETTINGS IN THE U.S. 1993-2004
Pathak P
, Martin BC
University
of Arkansas for Medical Sciences, Little Rock, AR, USA

PHP14
POLYPHARMACY IN ELDERLY PATIENTS AT THE MEXICAN INSTITUTE OF SOCIAL SECURITY: SATISFACTION AND COSTS

Constantino-Casas P
1, Torres-Arreola L1, Medécigo-Micete C1, Nevarez-Sida A1, Garcia-Contreras F1, García-Constantino M2
1
Mexican Institute of Social Security, Mexico City, Mexico, 2National Autonomous University of Mexico, México City, Mexico City, Mexico

PHP15
STUDYING THE IMPACT OF CO-PAYMENT DIFFERENTIAL ON GENERIC DISPENSING RATE IN A MANAGED CARE POPULATION

Meller CP
, Sekula R, Khandelwal NG, Lee KYWalgreens Health Services, Deerfield, IL, USA

PHP16
COMPARING GENERIC DISPENSING RATES AMONG THREE DIFFERENT RETAIL CHANNELS

Khandelwal NG
, Jiang JZ, Lee KY
Walgreens Health Services, Deerfield, IL, USA

PHP17
PREVALENCE OF CLINICALLY IMPORTANT POTENTIAL DRUG-DRUG INTERACTIONS IN REGIONE EMILIA ROMAGNA, ITALY

Gagne JJ
, Maio V, Rabinowitz C, Louis DZ
Thomas
Jefferson University, Philadelphia, PA, USA

PHP18
BENEFICIARY OUT-OF-POCKET: A CROSS-SECTIONAL PILOT STUDY IN THE SAUDI MINISTRY OF HEALTH HOSPITAL OUTPATIENT CLINICS

Alkelya MA

Saudi MOI, Directorate of Medical Services, Makkah, Makkah, Saudi Arabia

PHP19
RACE AND ASSOCIATED MEDICATION ADHERENCE IN MEDICAID ENROLLED PATIENTS WITH CHRONIC DISEASE

Balkrishnan R1, Uhas AA1, Anderson RT2

1
The Ohio State University College of Pharmacy, Columbus, OH, USA, 2Wake Forest University School of Medicine, Winston Salem, NC, USA

PHP20
IMPACT OF POLYPHARMACY MEDICATION THERAPY MANAGEMENT PROGRAM (MTMP) ON DRUG EXPENDITURES IN MEDICARE PART D POPULATION

Miller SA
1, Lou Y1, Mu Y1, Huang Z2, Lee KY2, Bertram CT2
1
Walgreens, Deerfield, IL, USA, 2Walgreens Health Services, Deerfield, IL, USA

PHP21
DETERMINANTS OF STATE MEDICAID PER CAPITA PRESCRIPTION DRUG EXPENDITURES: A STRUCTURE EQUATION MODELING APPROACH

Roy S
, Madhavan SS, Smith MJ, Douglas SM, Small SA
West Virginia
University, Morgantown, WV, USA

PHP22
HEALTH REIMBURSEMENT ACCOUNT BASED CONSUMER DRIVEN HEALTH PLANS:THEIR IMPACT ON MEDICAL UTILIZATION, PHARMACY UTILIZATION AND EXPENDITURES

Nair K
1, Park J2, Wolfe P1, Allen RR3, Saseen J1
1
University of Colorado at Denver and the Health Sciences Center, Denver, CO, USA, 2GlaxoSmithKline, Research Triangle Park, NC, USA, 3Peak Statistical Services, Evergreen, CO, USA

PHP23
NATIONAL SURVEY ON PRESCRIBERS' KNOWLEDGE OF AND THEIR SOURCE OF DRUG-DRUG INTERACTION INFORMATION

Ko Y1, Malone DC1, Skrepnek GH1, Armstrong EP1, Murphy JE1, Abarca J2, Rehfeld RA1, Reel SJ1, Woosley RL3

1
University of Arizona, Tucson, AZ, USA, 2WellPoint Next Rx, West Hills, CA, USA, 3The Critical Path Institute, Tucson, AZ, USA

PHP24
COMPARING MEDICATION ADHERENCE AND WASTAGE AMONG THREE DIFFERENT RETAIL PROGRAMS

Jiang JZ
, Khandelwal NG, Lee KY
Walgreens Health Services, Deerfield, IL, USA

PHP25
TRENDS IN OUT OF POCKET COST BURDEN FOR PATIENTS WITH CHRONIC CONDITIONS

Gleeson M
1, Patel V2, Zagari M2, Globe D2, Smith R1, Curkendall S3
1
Cerner, Beverly Hills, CA, USA, 2Amgen, Thousand Oaks, CA, USA, 3Cerner, Vienna, VA, USA

PHP26
MORE POLICY INITIATIVES IN THE AUSTRALIAN NATIONAL REIMBURSEMENT SYSTEM THAT WILL REDUCED COSTS DRAMATICALLY

Davey PJ

Radonomics Pty Ltd, Gordon, NSW, Australia

PHP27
HEALTH LOCUS OF CONTROL AND USE OF CONVENTIONAL AND ALTERNATIVE CARE: A COHORT STUDY

Tokuda Y
1, Takahashi O1, Ohde S1, Yanai H2, Hinohara S1, Fukui T1
1
St. Luke's Life Science Institute, Chuo, Tokyo, Japan, 2St. Luke's School of Nursing, Chuo, Tokyo, Japan

PHP28
ASSESSING LEVELS OF ASSOCIATION BETWEEN HEALTH-CARE EXPENDITURE AND HEALTH-CARE INDICATORS IN ECONOMICALLY DEVELOPED COUNTRIES

Gani R
, Ravndal F
Heron Evidence Development Ltd, Letchworth Garden City, Hertfordshire, UK

PHP29
REGULATION OF DRUG EXPENDITURES IN EUROPEAN COUNTRIES

Praznovcova L

Charles
University in Prague / Faculty of Pharmacy, Hradec Kralove, Czech Republic

PHP30
ATTITUDES OF CHAIN PHARMACY PERSONNEL TOWARD E-PRESCRIBING

Rupp MT
1, Warholak-Jackson T2
1
Midwestern University - Glendale, Glendale, AZ, USA, 2University of Arizona, Tucson, AZ, USA

PHP31
EXAMINATION OF THE VALUE OF LAB DATA IN HEALTH CARE MANAGEMENT

Ye X
, Gams E, Anetsberger H, Asch K, Sun SX, Lee KY, Bertram CT
Walgreens Health Services, Deerfield, IL, USA

PHP32
THE STATE OF HEALTH STATUS MEASUREMENT IN LATIN AMERICA

Zarate V
1, Kind P2
1
Pontificia Universidad Catolica de Chile, Santiago, Chile, 2Outcomes Research Group, Centre for Health Economics, University of York, York, UK

PHP33
PRELIMINARY RESULTS OF A NEW NURSE-PHARMACIST CLINICAL PREVENTION PROGRAM

Krueger KP
1, Hunter ML1, Fiske M2, Campbell S2, Macnee C1
1
University of Wyoming, Laramie, WY, USA, 2The HCMS Group, Cheyenne, WY, USA

PHP34
EXAMINING THE ASSOCIATION BETWEEN EXPOSURE RATES TO CLINICALLY IMPORTANT DRUG-DRUG INTERACTIONS AND PHARMACEUTICAL SERVICES WITHIN AMBULATORY CARE SETTING IN VETERANS AFFAIRS MEDICAL CENTERS

Mahmood MH
, Armstrong EP, Malone DC, Skrepnek GH
University
of Arizona, College of Pharmacy, Tucson, AZ, USA

PHP35
BREAK-EVEN COST ANALYSIS OF MEDICATION THERAPY MANAGEMENT PROGRAMS FOCUSING ON ADVERSE DRUG EVENT PREVENTION

Ying X
, Touchette D
University
of Illinois at Chicago, Chicago, IL, USA

PHP36
GENERIC PRESCRIPTION AND PHYSICIANS QUALITY PERCEPTION IN ARGENTINA: THE EXPERIENCE OF THE REMEDIAR PROGRAM

Kremer P1, Maceira DA2

1
Center for the Implementation of Public Policies Towards Equity and Growth (CIPPEC), Ciudad Autónoma de Buenos Aires, Capital Federal, Argentina, 2Center for the Study of the State and Society - Center for the Implementation of Public Policies Towards Equity and Growth, Ciudad Autónoma de Buenos Aires, Argentina

PHP37
THE MARKET SHARE OF PRIVATE FOR-PROFIT AND NON-PROFIT HEALTH CARE PROVIDERS FROM THE HUNGARIAN HEALTH INSURANCE BUDGET

Boncz I
1, Dózsa C2, Sebestyén A1, Oláh A3, Betlehem J3, Gulácsi L4
1
National Health Insurance Fund Administration, Budapest, Hungary, 2Ministry of Health, Budapest, Hungary, 3University of Pécs, Pécs, Hungary, 4Corvinus University of Budapest, Budapest, Hungary

PHP38
SAME-DAY DISCHARGES FROM THE HOSPITAL TO THE HOME: IMPLICATIONS OF THE LACK OF A SHORT-STAY UNIT IN THE EMERGENCY ROOM

Kim SH

Florida
International University, Miami, FL, USA

PHP39
QUALITY ASSESSMENT OF PHARMACOECONOMIC EVALUATIONS SUBMITTED FOR REIMBURSEMENT IN KOREA

Lim SH, Kwon EY, Cho SC, Bae EY, Yi SY, Kim BY

Health Insurance Review Agency, Seoul, South Korea

PHP40
EFFECTS OF EDUCATIONAL INTERVENTION ON PRESCRIPTION WRITING IN PUBLIC AND PRIVATE HOSPITALS IN BENIN CITY, NIGERIA

Akoria OA
, Isah A
University of Benin
, Benin City, Edo State, Nigeria

PHP41
HYSICIANS' ATTITUDES TOWARD E-DETAILING: (A PILOT STUDY)

Alkhateeb FM
, Doucette WR
University of Iowa, Iowa city, IA, USA

PHP42
CORRELATION BETWEEN COLLEGE STUDENT ACTIVITIES AND TWO PRODUCTIVITY MEASUREMENTS

Dhing CW
, Stein G, Pal S, Mackey ML
St. John's
University, Queens, NY, USA

PHP43
ANALYSIS OF COMMUNITY PHARMACISTS' INTERVENTIONS ON ELECTRONIC PRESCRIPTION ERRORS

Warholak-Jackson T
1, Rupp MT2
1
University of Arizona, Tucson, AZ, USA, 2Midwestern University - Glendale, Glendale, AZ, USA

PHP44
PHARMACIST WORKLOAD AND PHARMACY CHARACTERISTICS ASSOCIATED WITH THE DISPENSING OF POTENTIALLY CLINICALLY IMPORTANT DRUG-DRUG INTERACTIONS

Malone DC
1, Abarca J2, Skrepnek GH1, Murphy JE1, Armstrong EP1, Grizzle AJ1, Rehfeld RA1, Woosley RL3
1
University of Arizona, Tucson, AZ, USA, 2WellPoint Next Rx, West Hills, CA, USA, 3The Critical Path Institute, Tucson, AZ, USA

PHP45
DID FDAMA SECTION 114 LEAD TO A DECLINE OF ECONOMIC-CONTENT DRUG ADVERTISING IN MEDICAL JOURNALS?

Palmer JA
, Neumann PJ, Timm AR
Tufts-New
England Medical Center, Boston, MA, USA

PHP46
THE RELATIVE PERFORMANCE OF PHARMACEUTICAL SECTOR SECURITY PRICES DURING STOCK MARKET CRASHES

Skrepnek GH
, Fishman JC, Yancy ML
University
of Arizona, Tucson, AZ, USA

PHP47
DETERMINING ANTIBIOTIC USE IN INDIA

Kotwani A1, Wattal C2, Holloway K3, Sorensen TL4, Roy Chaudhury R5
1Patel Chest Institute, University of Delhi, Delhi, India, 2Sir Ganga Ram Hospital, New Delhi, India, 3World Health Organisation, Geneva, Switzerland, 4Municipality Administration, Helsingor, Denmark, 5International Clinical Epidemiology Network (INCLEN), New Delhi, India

CARDIOVASCULAR DISEASE

Clinical Outcomes Studies

PCV1
COMPARING THE RISKS OF DEVELOPING STROKE IN UNCOMPLICATED HYPERTENSIVE PATIENTS TREATED WITH DIFFERENT ANTI-HYPERTENSIVE DRUGS

Liu PH
, Wang JD
National
Taiwan University, College of Public Health, Taipei, Taiwan

PCV2
CLINICAL EXPERIENCE IN DYSLIPIDEMIC PATIENTS TREATED EITHER WITH ROSUVASTATIN 10 MG/DAY OR EZETIMIBE/ SIMVASTATIN 10/20 MG/DAY IN MEXICO CITY. A RETROSPECTIVE ANALYSIS

Gomez-Briceño GA

Manuel Gea Gonzalez Hospital
, Mexico City, Mexico

PCV3
HYPERTENSION MAY NOT INFLUENCE CARDIOVASCULAR BENEFITS OF STATIN THERAPY. RESULTS FROM A META-REGRESSION ANALYSIS OF 69,984 PATIENTS

Messerli F
1, Pinto L2, Tang S3, Thakker K3, Dubois RW2
1
St. Luke's-Roosevelt Hospital, New York, NY, USA, 2Cerner Health Insights, Beverly Hills, CA, USA, 3Pfizer Global Pharmaceuticals, New York, NY, USA

PCV4
UMULATIVE PERSISTENCE OF ANTIHYPERTENSIVE MEDICATION AS A NEWLY PRESCRIBED DRUG IN A MEDICAID POPULATION

Gu A
1, Shaya FT1, Weir MR2
1
University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland, Baltimore, MD, USA

PCV5
NON-PERSISTENT USE OF ANTIHYPERTENSIVE DRUGS INCREASES RISK OF HOSPITALIZATIONS FOR STROKE BY NEARLY 20%

Breekveldt-Postma NS
1, Siiskonen SJ1, Penning-van Beest FJA1, Erkens JA1, Vincze G2, Falvey H2, Herings RMC1
1
PHARMO Institute, Utrecht, The Netherlands, 2Novartis Pharma AG, Basel, Switzerland

PCV6
NON-PERSISTENT USE OF ANTIHYPERTENSIVE DRUGS INCREASES RISK OF HOSPITALIZATIONS FOR ACUTE MYOCARDIAL INFARCTION BY 10% IN PATIENTS WITH LOW OR INTERMEDIATE CARDIOVASCULAR RISK

Breekveldt-Postma NS
1, Siiskonen SJ1, Penning-van Beest FJA1, Erkens JA1, Vincze G2, Falvey H2, Herings RMC1
1
PHARMO Institute, Utrecht, The Netherlands, 2Novartis Pharma AG, Basel, Switzerland

PCV7
ELATIONSHIPS BETWEEN VENOUS THROMBOEMBOLIC (VTE) PROPHYLACTIC TREATMENTS AND VTE COMPLICATIONS OR THROMBOCYTOPENIA AND AMONG VETERANS RECEIVING TOTAL HIP REPLACEMENTS

Raisch DW
, Campbell HM, Taylor Z
Department of Veterans Affairs Cooperative Studies Program, Albuquerque, NM, USA

PCV8
RISK OF MYOPATHY ASSOCIATED WITH THE USE OF STATINS AND POTENTIALLY INTERACTING MEDICATIONS – A RETROSPECTIVE ANALYSIS

Shah S
1, Shepherd MD2, Barner J2, Wilson JP2, Lawson K2
1
Bayer Pharmaceuticals Corporation, West Haven, CT, USA, 2University of Texas at Austin, Austin, TX, USA

PCV9
ISOLATED SYSTOLIC HYPERTENSION IN A COHORT OF INNER CITY MINORITY PATIENTS

Shaya FT, Gu A
University of Maryland School of Pharmacy, Baltimore, MD, USA

PCV10
CLINICAL OUTCOME OF HYPERTENSION MANAGEMENT: A FIVE YEAR OBSERVATIONAL STUDY

Lee VWY, Chan TH, Ko TT, Lee KK, Tomlinson B
The Chinese University of Hong Kong, Hong Kong, China

PCV11
THE EFFECTS OF SEASONAL VARIATIONS AND WEATHER CONDITIONS ON THE OCCURRENCE OF HEART ATTACKS IN HUNGARY BETWEEN 2000-2004

Kriszbacher I1, Boncz I2, Oláh A1, Bódis J1
1University of Pécs, Pécs, Hungary, 2National Health Insurance Fund Administration, Budapest, Hungary

PCV12
SEASONAL VARIATIONS OF THE OCCURRENCE OF ACUTE MYOCARDIAL INFARCTION IN HUNGARY BETWEEN 2000-2004

Kriszbacher I1, Boncz I2, Oláh A1, Bódis J1
1University of Pécs, Pécs, Hungary, 2National Health Insurance Fund Administration, Budapest, Hungary

PCV13
METABOLIC SYNDROME PREVALENCE IN A HYPERTENSIVE POPULATION

Shaya FT1, Gu A1, Saunders E2 1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland School of Medicine, Baltimore, MD, USA

PCV14
SURVIVAL ANALYSIS OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION ACCORDING TO HOSPITAL TYPE
Boncz I1, Takács E2, Belicza É2, Sebestyén A1, Kriszbacher I3, Oláh A3, Bódis J3 1National Health Insurance Fund Administration, Budapest, Hungary, 2Semmelweis University, Budapest, Hungary, 3University of Pécs, Pécs, Hungary

PCV15
NEW DIAGNOSIS OF HYPERTENSION AMONG CELECOXIB AND NON-SELECTIVE NSAID USERS: A POPULATION-BASED COHORT STUDY

Wang J1, Mullins CD1, Mamdani M2, Rublee DA2, Shaya FT1
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Pfizer, Inc, New York, NY, USA

Cost Studies

PCV16
AN ECONOMIC ASSESSMENT OF THE CONTROL AND DETENTION PROGRAMS IN HYPERTENSIVE MEXICAN POPULATION (2005-2025)

Salinas-Escudero G1, Contreras-Hernandez I1, Duran-Arenas L1, Garduño-Espinosa J1, Mould-Quevedo J2
1
Social Security Mexican Institute, Mexico City, Mexico, 2Pfizer Mexico, Mexico City, Mexico

PCV17
COMPARING THE COST OF MICROSURGERY AND RADIOSURGERY FOR THE MANAGEMENT OF VESTIBULAR SCHWANNOMA

Banerjee R, Moriarty J, Pollock B, Foote R
Mayo Clinic, Rochester, MN, USA

PCV18
WITHDRAWN

PCV19
COST COMPARISON OF DIFFERENT TREATMENTS FOR DEEP VEIN THROMBOSIS PROPHYLAXIS DURING ABDOMINAL SURGERY

Patel VA, McGhan WF
University of the Sciences in Philadelphia, Philadelphia, PA, USA

PCV20
A COST-EFFECTIVENESS STUDY COMPARING IVABRADINE WITH STANDARD CARE IN STABLE ANGINA PECTORIS IN THE NETHERLANDS

Redekop WK1, Nuijten MJC2
1Erasmus Medical Center, Rotterdam, The Netherlands, 2Erasmus University, Rotterdam, The Netherlands

PCV21
ECONOMIC EVALUATION OF EPLERENONE COMPARED WITH PLACEBO IN PATIENTS WITH MYOCARDIAL INFARCTION COMPLICATED BY LEFT VENTRICULAR SYSTOLIC DYSFUNCTION AND HEART FAILURE IN MEXICO

Mould-Quevedo J, Salomon-Molina A, Davila-Loaiza G
Pfizer Mexico, Mexico City, Mexico

PCV22
A CARDIOVASCULAR DISEASE COST-EFFECTIVENESS MODEL BASED ON CTT META-ANALYSIS

Lundy J1, Davies GM2, Cook JR2
1University of Arizona, Tucson, AZ, USA, 2Merck and Co. Inc, North Wales, PA, USA

PCV23
EVALUATION OF DYSLIPIDEMIA THERAPIES FOR TREATMENT OF LOW HDL AND HIGH LDL: A COST-EFFECTIVENESS ANALYSIS BASED ON NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY III

Malone DC1, Charland SL2
1University of Arizona, Tucson, AZ, USA, 2Kos Pharmaceuticals, Inc, Cranbury, NJ, USA

PCV24
USE OF A DECISION ANALYTIC MODEL TO EVALUATE COST PER PATIENT TREATED TO GOAL WITH HIGH POTENCY ANTILIPIDEMICS

Moore E
, Tiller KW, Allerman AA, Mistry HH, Trice S, Devine JW
Department of Defense Pharmacoeconomic Center, Fort Sam Houston, TX, USA

PCV25
THE ECONOMIC AND HEALTH CONSEQUENCES IN MEXICO OF MANAGING HYPERTENSION AND HYPERCHOLESTEROLEMIA WITH A SINGLE PILL THERAPY

Mould-Quevedo J
, Salomon-Molina A, Davila-Loaiza G
Pfizer Mexico, Mexico City, Mexico

PCV26
COST-EFFECTIVENESS OF ROSUVASTATIN AND EZETIMIBE/SIMVASTATIN IN PATIENTS WITH DYSLIPIDEMIA IN MEXICO CITY

Gomez-Briceño GA1, Mino D2
1
Manuel Gea Gonzalez Hospital, Mexico City, Mexico, 2Instituto Mexicano de Seguro Social, México D.F, México, Mexico

PCV27
CLINICAL AND ECONOMIC BURDEN OF NONADHERANCE TO LIPID-LOWERING AND ANTIHYPERTENSIVE THERAPY IN A HYPERTENSIVE POPULATION

Cherry S1, Benner JS1, Hussein M1, Tang S2, Nichol MB3
1ValueMedics Research, LLC, Falls Church, VA, USA, 2Pfizer Global Pharmaceuticals, New York, NY, USA, 3University of Southern California, Los Angeles, CA, USA

PCV28
A COST-EFFECTIVENESS ANALYSIS FOR PROPHYLACTIC THERAPIES AGAINST AIR TRAVELER THROMBOSIS

Spooner JJ1, Gandhi PK2, Bullano M3
1
University of the Sciences in Philadelphia, Philadelphia, PA, USA, 2University of Florida-Gainesville, Gainesville, FL, USA, 3AstraZeneca, LP, Wilmington, DE, USA

PCV29
PHARMACOECONOMIC ANALYSIS OF EXTENDED PROPHYLAXIS BY ENOXAPARIN AFTER HIP JOINT REPLACEMENT

Lomakin A
, Kulikov A
Moscow
Medical Academy, Moscow, Russia

PCV30
COST-EFFECTIVENESS AMONG BRAND AND GENERIC STATINS BASED ON REAL-WORLD EFFECTIVENESS: IMPLICATIONS FOR STATIN FORMULARY DESIGN

Ohsfeldt RL
1, Gandhi SK2, Fox KM3
1
Texas A & M Health Science Center, College Station, TX, USA, 2AstraZeneca, LP, Wilmington, DE, USA, 3University of Maryland School of Medicine, Monkton, MD, USA

PCV31
COST-EFFECTIVENESS OF ACHIEVING ADDITIONAL LIPID TARGETS WHEN SUBSTITUTING FENOFIBRATE 145MG FOR STANDARD FENOFIBRATE THERAPY

Sorensen SV1, Frick KD2, Burge R3, Simko RJ3
1
United BioSource Corporation, Bethesda, MD, USA, 2Johns Hopkins University, Baltimore, MD, USA, 3Abbott Laboratories, Abbott Park, IL, USA

PCV32
IMPACT OF DEPRESSION ON HEALTH STATUS AND HEALTH CARE UTILIZATION IN PATIENTS WITH HYPERTENSION: RESULTS FROM THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS 2002-2003)

Shi L, Liao EK, Khan M
Tulane
University, New Orleans, LA, USA

PCV33
ANALYSIS OF CLOPIDOGREL USE IN OUTPATIENT SETTINGS

Bae JP1, Bellebaum KL2, McCollam PL11Eli Lilly and Company, Indianapolis, IN, USA, 2Ohio State University, Columbus, OH, USA

PCV34
COST OF CONSUMABLES ASSOCIATED WITH CARDIOVASCULAR COMPUTED TOMOGRAPHY ANGIOGRAPHY: THE CARDIOLOGIST'S PERSPECTIVE

Vishalpura T1, Callister TQ2, Sarnes MW3
1
Xcenda, Yardley, PA, USA, 2Tennessee Heart and Vascular Institute, P.C, Hendersonville, TN, USA, 3Xcenda, Palm Harbor, FL, USA

PCV35
IMPACT OF NESIRITIDE ON TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE (ADHF): EVIDENCE FROM A US HOSPITAL DATABASE

DiDomenico R1, Sengupta N2, Barker C2

1
University of Illinois at Chicago, Chicago, IL, USA, 2Scios Inc, Mountain View, CA, USA

Health Care Use & Policy Studies

PCV36
THE EFFECT OF DRUG COST-SHARING ON ADHERENCE TO CHRONIC MEDICATIONS

Patrick A
1, Maclure M2, Dormuth C3, Glynn RJ4, Schneeweiss S5
1
Brigham and Women's Hospital, Boston, MA, USA, 2University of Victoria, Victoria, BC, Canada, 3University of British Columbia, Vancouver, BC, Canada, 4Harvard Medical School / Brigham and Women's Hospital, Boston, MA, USA, 5Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

PCV37
THE IMPACT OF CARE GAP IN MANAGING HIGH CARDIOVASCULAR RISK PATIENTS: A CANADIAN POPULATION ANALYSIS

Grima DT1, Langer A2, Leiter L3, Attard C1, Chow CM3, Goodman S2
1
Cornerstone Research Group Inc, Burlington, ON, Canada, 2Canadian Heart Research Centre, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada

PCV38
TREATMENT OF DEPRESSION IN CORONARY ARTERY DISEASE: A STUDY OF NATIONAL AMBULATORY MEDICAL CARE VISITS FROM 2000 TO 2004

Sankaranarayanan J, Dobesh P
University of Nebraska Medical Center, Omaha, NE, USA

PCV39
TRENDS IN THE OFF-LABEL PRESCRIBING OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A (HMG-COA) REDUCTASE INHIBITORS IN THE UNITED STATES: 1998 TO 2004.

Bodhani A, Karve S, Martin BC
University
of Arkansas for Medical Sciences, Little Rock, AR, USA

PCV40 - WITHDRAWN

PCV41
UTILIZATION AND COMPLIANCE OF CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF HYPERTENSION IN THE LOUISIANA MEDICAID PROGRAM

Valderrama A, Blake S, Sherman J
The University of Louisiana at Monroe, Monroe, LA, USA

PCV42
USE OF RECOMMENDED MEDICATIONS AFTER MYOCARDIAL INFARCTION IN AUSTRIA

Winkelmayer WC
1, Bucsics A2, Kaiser A3, Pogantsch M3
1
Brigham and Women's Hospital, Boston, MA, USA, 2Main Association of Austrian Social Security Institutions, Vienna, Austria, 3Styrian Regional Sickness Fund, Graz, Austria

PCV43
PREDICTORS OF CLOPIDOGREL THERAPY PERSISTENCE IN ACUTE CORONARY SYNDROME PATIENTS

McCollam PL
1, Shetty SS2
1
Eli Lilly and Company, Indianapolis, IN, USA, 2i3 Magnifi, An Ingenix Company, Eden Prairie, MN, USA

PCV44
EFFECTS OF MEDICAID ACCESS RESTRICTIONS ON STATIN UTILISATION FOR PATIENTS TREATED BY PHYSICIANS PRACTISING IN POOR AND MINORITY NEIGHBORHOODS

Headen AE1, Axelsen KJ2

1
North Carolina State University, Raleigh, NC, USA, 2Pfizer Pharmaceuticals, New York, NY, USA

PCV45
ARE MINORITIES MORE LIKELY TO BE INITIALLY DIAGNOSED OF HYPERTENSION DURING NON-OFFICE-BASED VISITS? EVIDENCE FROM MEDICAL EXPENDITURE PANEL SURVEY 1996-2003

Li C

University
of Arkansas for Medical Sciences, Little Rock, AR, USA

PCV46
EFFECT OF MENTAL DISORDERS ON HEALTH CARE COST AMONG ELDERLY WITH DISEASES OF THE HEART

Husaini BA
1, Hull P1, Cain V1, Samad Z1, Sherkat D2, Levine R3
1
Tennessee State University, Nashville, TN, USA, 2Southern Illinois University, Carbondale, IL, USA, 3Morehouse School of Medicine & Tennessee State University, Nashville, TN, USA

PCV47
BURDEN OF ILLNESS AMONG PATIENTS AT HIGH RISK FOR MAJOR CARDIOVASCULAR EVENTS

Harley C1, Zema C2, Cao F3, Ye X1, Shah H2
1
i3 Innovus, Eden Prairie, MN, USA, 2Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA, 3i3 Innovus, Reston, VA, USA

PCV48
IMPACT OF MEDICAID PREFERRED DRUG LISTS ON THERAPEUTIC ADHERENCE
<
Ridley D1, Axelsen K2
1
Duke University, Durham, NC, USA, 2Pfizer Pharmaceuticals, New York, NY, USA

PCV49
DEVELOPMENT OF AN INTERACTIVE MODEL TO PREDICT LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL) REDUCTION AND LDL GOAL ATTAINMENT ASSOCIATED WITH STATIN USE IN ROUTINE CLINICAL PRACTICE

Kamat S1, Willey VJ1, Cziraky MJ2, Sweet B3
1
HealthCore, Wilmington, DE, USA, 2HealthCore, Inc, Wilmington, DE, USA, 3WellPoint, Grand Island, NY, USA

PCV50 - Withdrawn

PCV51
PROCEDURAL MIX AND VOLUME DURING THE FIRST YEAR OF OWNERSHIP OF A COMPUTED TOMOGRAPHY ANGIOGRAPHY SCANNER: EVIDENCE FROM A LARGE CARDIOLOGY PRACTICE

Vishalpura T1, Callister TQ2, Sarnes MW3

1
Xcenda, Yardley, PA, USA, 2Tennessee Heart and Vascular Institute, P.C, Hendersonville, TN, USA, 3Xcenda, Palm Harbor, FL, USA

PCV52
THE IMPACT OF SIMVASTATIN LAUNCHING ON EXISTING LIPITOR PATIENTS IN A MANAGED CARE SETTING

Jiang JZ, Fuldeore M, Huang Z, Meller CP, Khandelwal NG, Lee KY
Walgreens Health Services, Deerfield, IL, USA

PCV53
PROFILES OF INITIAL DRUG THERAPIES AMONG NEWLY DIAGNOSED HYPERTENSIVE PATIENTS WITH NO COMPELLING INDICATIONS

Ganguli A, Dr. Hong SH
University
of Tennessee, Memphis, TN, USA

PCV54
PROJECTED COST SAVINGS COMPARISON TO THIRD PARTY PAYERS FOR THE YEAR FOLLOWING GENERIC SIMVASTATIN AND PRAVASTATIN AVAILABILITY IN THE US

Gandhi PK1, Spooner JJ2, Groesbeck JM2, Segal R1
1
University of Florida-Gainesville, Gainesville, FL, USA, 2Advanced Concepts Institute, Philadelphia, PA, USA

PCV55
BLOOD PRESSURE CONTROL THROUGH PATIENT AND PHYSICIAN EDUCATION PROGRAMS

Shaya FT1, Gu A1, Saunders E2
1
University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland School of Medicine, Baltimore, MD, USA

PCV56
THE COST-EFFECTIVENESS LANDSCAPE OF GENETIC TESTING WITH WARFARIN THERAPY

Meckley LM1, Austin MJF2, Garrison LP1, Veenstra DL1
1
University of Washington, Seattle, WA, USA, 2F. Hoffmann-La Roche AG, Basel, Switzerland

PCV57
HOW INFLUENTIAL ARE CLINICAL GUIDELINES FOR THE EVALUATION OF ACUTE CARDIAC SYMPTOMS? METHODOLOGY FOR THE INVESTIGATION OF NATIONAL CORONARY DISEASE IDENTIFICATION (INCIDENT)

Li J1, Reaven NL2, Funk SE2, Schabert VF2, Lovett JE2, DeMaria AN3
1
Harvard Medical School, La Canada, CA, USA, 2Strategic Health Resources, La Canada, CA, USA, 3University of California, San Diego, La Canada, CA, USA

PCV58
HOSPITAL POLICIES FOR TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE

Vats V
1, DiDomenico R1, Wojtynek JE2, Theobald JC2, Schumock GT1
1
University of Illinois at Chicago, Chicago, IL, USA, 2Consorta Inc, Schaumburg, IL, USA

Methods &Concepts

PCV59
EFFECTIVENESS OF OUTPATIENT CLOPIDOGREL TREATMENT IN PREVENTING CARDIOVASCULAR EVENTS IN PATIENTS UNDERGOING STENTING FOR ACS: A RETROSPECTIVE CLAIMS DATABASE ANALYSIS
Riedel AA1, Chastek BJ1, Wygant G2, Hauch O2
1
i3Innovus, Eden Prairie, MN, USA, 2AstraZeneca LP, Wilmington, DE, USA

PCV60
THE CLIN-O-GRAM: A GRAPHICAL TOOL DESCRIBING DRUG USE PRIOR TO CLINICAL OUTCOMES

Gause D, Preblick R, Levy D, Raghavan K
Novartis Pharmaceuticals, East Hanover, NJ, USA

PCV61
DIFFERENCES IN ANTIBIOTICS PRESCRIBED BY PHYSICIANS WITH HIGH AND LOW INFECTION RATES APPLIED TO PATIENTS UNDERGOING CARDIOVASCULAR SURGERY

Cerrito PB1, Cerrito JC2
1
University of Louisville, Louisville, KY, USA, 2Kroger Pharmacy, Louisville, KY, USA

PCV62
ASSESSING SYSTEMATIC DIFFERENCES IN PHYSICIAN'S TENDENCY TO REPORT ROUNDED BLOOD PRESSURE MEASUREMENTS

Ishak KJ1, Payne K1, Caro JJ2, Khan ZM3, Daley W4, Califf R5
1Caro Research Institute, Montreal, QC, Canada, 2Caro Research Institute, Concord, MA, USA, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals Corporation, Florham Park, NJ, USA, 5Duke University Medical Center, Durham, NC, USA

PCV63
DYNAMIC OPTIMIZATION IN THE TREATMENT OF HYPERLIPIDEMIA

Hughen WK1, Vernon JA1, Willke RJ2

1
University of Connecticut, Storrs, CT, USA, 2Pfizer Inc, Bridgewater, NJ, USA

PCV64
FACTOR SCREENING FOR PARSIMONY OF VARIABLES IN PHARMACOECONOMIC MODELS

Klein RW
1, Yaesoubi R2, Roberts SD2
1
Medical Decision Modeling Inc, Indianapolis, IN, USA, 2North Carolina State University, Raleigh, NC, USA

PCV65
DRUG-DRUG INTERACTIONS ON ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR PRESCRIPTIONS IN THE UNITED STATES: 2001 TO 2004

Lai L, Gharib S
Nova Southeastern University, Ft. Lauderdale, FL, USA

PCV66
MODELED ACHIEVEMENT OF OPTIMAL LIPID VALUES AND ASSOCIATED CARDIOVASCULAR EVENT RATES WITH EXTENDED-RELEASE NIACIN/SIMVASTATIN, EZETIMIBE/SIMVASTATIN, AND INDIVIDUAL AGENTS IN A MANAGED CARE POPULATION

Charland SL1, Quimbo R2, Cziraky MJ2, Weathermon RA1, Stanek EJ1
1
Kos Pharmaceuticals, Inc, Cranbury, NJ, USA, 2HealthCore, Inc, Wilmington, DE, USA

PCV67
USING AN INTERNATIONAL DATABASE OF ACUTE CORONARY EVENTS TO ASSESS TODAY'S
PRACTICE PATTERNS AND DESCRIBE TREATMENT STRATEGIES IN THE HOSPITAL SETTING
Nasuti PI, Hamad B, Yeung E
IMS Health, London, UK

PCV68
IS META-ANALYSIS ALWAYS A GOOD IDEA?

Xenakis JG, Huybrechts KF, Caro JJ
Caro Research Institute, Concord, MA, USA

PCV69
BLOOD PRESSURE SUCCESS ZONE LONGITUDINAL STUDY OF SUCCESS (BPSZ-BLISS). AN OBSERVATIONAL, MULTI-CENTER STUDY OF THE IMPACT OF THE BPSZ EDUCATIONAL PROGRAM ON BLOOD PRESSURE CONTROL, PERSISTENCE, COMPLIANCE, AND TREATMENT SATISFACTION. DESIGN AND METHODS

Payne K1, Caro JJ2, Daley W3, Khan ZM4, Ishak KJ1, Stark K3, Flack JM5, Velázquez EJ6, Nesbitt SD7, Califf R6
1
Caro Research Institute, Montreal, QC, Canada, 2Caro Research Institute, Concord, MA, USA, 3Novartis Pharmaceuticals Corporation, Florham Park, NJ, USA, 4Novartis Pharma AG, Basel, Switzerland, 5Wayne State University, Detroit, MI, USA, 6Duke University Medical Center, Durham, NC, USA, 7University of Texas Southwestern Medical Center, Dallas, TX, USA

Patient-Reported Outcomes 

PCV70
MOBILE PHONE MESSAGE VERSUS POSTAL REMINDERS TO INCREASE TREATMENT ADHERENCE AFTER LIPID LOWERING THERAPY AMONG HYPERLIPIDEMIC PATIENTS IN PRIMARY CARE

Kim YS
, Cho SJ
University
of Ulsan College of Medicine, Seoul, South Korea

PCV71
THE IMPACT OF INTERACTIVE VOICE RECOGNITION TECHNOLOGY ON ADHERENCE TO STATIN THERAPY

Patel MH1, Schaaf DT2, Flores DN3, Fleszar GJ1, Jan SA1"
1
Horizon Blue Cross Blue Shield of New Jersey, Newark, NJ, USA, 2Pfizer, Inc, New York, NY, USA, 3Pfizer, Inc, Morris Plains, NJ, USA

PCV72
CHARACTERIZATION OF HYPERTENSIVE PATIENTS WHO MIGHT BENEFIT FROM A COMBINATION OF TWO DRUGS IN ONE PILL FOR REDUCTION OF CARDIOVASCULAR RISK

Sturkenboom MC1, Van der Hoeven-Borgman R1, Van Kints A1, Moller RA2, Fitzgerald K3, Rosa K4, Picelli G5, Cramer JA6, Mazzaglia G7, Cricelli C7, Niccolai C7
1
Erasmus University Medical Center, Rotterdam, The Netherlands, 2Pfizer, New York, NY, USA, 3Mapi Values, Boston, MA, USA, 4Mapi Values USA LLC, Boston, MA, USA, 5International Pharmacoepidemiology and Pharmacoeconomics Research Center, Desio, Italy, 6Yale University School of Medicine, West Haven, CT, USA, 7Italian College of General Practioners, Florence, Italy

PCV73
DESCRIBING DRUG USE PATTERNS USING SEQUENCE ANALYSIS

Gause D
, Lau H
Novartis Pharmaceuticals, East Hanover, NJ, USA

PCV74
DEVELOPMENT AND VALIDATION OF THE HEALTH-RELATED QUALITY OF LIFE (HRQL) COMPONENT OF THE HYBRID INSTRUMENT--IMPACT (IMPACT OF PHARMACIST ACTIVITIES AND CARE ON TREATMENT OUTCOMES)

Bounthavong M, Law AV
Western
University of Health Sciences, Pomona, CA, USA

PCV75
LINGUISTIC VALIDATION OF THE KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE IN 30 LANGUAGES

Kim J
1, Chevallet L2, Spertus J3
1
Amgen Inc, Thousand Oaks, CA, USA, 2Mapi Research Institute, Lyon, Rhone, France, 3University of Missouri, Kansas City, MO, USA

DIABETES

Clinical Outcomes Studies 

PDB1
RECENT TRENDS IN OBESITY-RELATED CO-MORBIDITIES AND MEDICAL COSTS IN THE US

Liu G1, Tian H2, Le TK3, Zhao Z3
1
Peking University, Beijing, China, 2RAND Corporation, Santa Monica, CA, USA, 3Eli Lilly and Company, Indianapolis, IN, USA

PDB2
GLYCAEMIC AND WEIGHT EFFECTS OF EXENATIDE FOR DIFFERENT AGE GROUPS

Wintle M
1, Guan X1, Mac S1, Brodows R2, Kim D1
1
Amylin Pharmaceuticals, Inc, San Diego, CA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA

PDB3
A RETROSPECTIVE EVALUATION OF HBA1C GOAL ATTAINMENT AMONG VARIOUS DIABETES TREATMENT REGIMENS IN A MANAGED CARE POPULATION

Abarca J
1, White TJ2, Langley P3, Yokoyama K4, Campbell HE2
1
WellPoint Next Rx, Tucson, AZ, USA, 2WellPoint Next Rx, West Hills, CA, USA, 3University of Minnesota, Minneapolis, MN, USA, 4WellPoint Next Rx, West Hills, AZ, USA

PDB4
HE EFFECTIVENESS OF DANCE THERAPY AMONG ADULT PATIENTS WITH DIABETES MELLITUS TYPE II

Járomi M1, Kalman A1, Oláh A1, Boncz I2, Betlehem J1
1
University of Pécs, Pécs, Hungary, 2National Health Insurance Fund Administration, Budapest, Hungary

PDB5
BODY WEIGHT GAIN EXPERIENCED BY DIABETIC PATIENTS DUE TO THIAZOLIDINEDIONES (TZDS): META-ANALYSIS OF PUBLISHED RANDOMIZED SHORT-TERM CLINICAL TRIALS

Phatak HM
, Yin D
Merck & Co., Inc, Whitehouse Station, NJ, USA

PDB6
RACIAL DIFFERENCES IN HOSPITALIZATIONS ASSOCIATED WITH MEDICATION USE IN MEDICAID ENROLLEES WITH TYPE 2 DIABETES

Shenolikar R, Balkrishnan R
The Ohio State University College of Pharmacy, Columbus, OH, USA

Cost Studies 

PDB7
BUDGET IMPACT ANALYSIS OF PIOGLITAZONE FOR DIABETES IN TAIWAN: A RETROSPECTIVE DATABASE ANALYSIS

Tang SL1, Tarn YH2
1
Tri-Service General Hospital, Taipei, Taiwan, 2College of Pharmacy, Taipei Medical University, Taipei, Taiwan

PDB8
COST-BENEFIT ANALYSIS OF INHALED INSULIN: A CANADIAN PERSPECTIVE

Sadri H
University
of Toronto, Toronto, ON, Canada

PDB9
DIRECT AND INDIRECT COSTS AND RESOURCE UTILIZATION ASSOCIATED WITH PHOTOCOAGULATION AND VITRECTOMY PROCEDURES AMONG EMPLOYEES WITH DIABETIC RETINOPATHY

Yu APan>
1, Cahill KE1, Birnbaum HG1, Lee LJ2, Oglesby AK2, Tang J1, Qiu Y1
1
Analysis Group, Inc, Boston, MA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA

PDB10
A PHARMACOECONOMIC EVALUATION FOR THE TREATMENT OF MEXICAN PATIENTS WITH DIABETES TYPE 2

Contreras-Hernandez I
1, Mould-Quevedo J2, Salinas-Escudero G1, Pacheco-Dominguez RL3, Castro-Martínez G4, Davila-Loaiza G2, Garduño-Espinosa J1
1
Social Security Mexican Institute, Mexico City, Mexico, 2Pfizer Mexico, Mexico City, Mexico, 3Social Security Mexican Institute, Mexico City, Federal District, Mexico, 4Social Security Mexican Institute, Mexico City, Mexico, Federal District, Mexico

PDB11
THE COST-EFFECTIVENESS OF VACUUM ASSISTED CLOSURE® (V.A.C.) THERAPY FOR THE TREATMENT OF DIABETIC FOOT WOUNDS

Flack SM1, Apelqvist J2, Trueman P1, Keith MS3, Williams DV4

1
York Health Economics Consortium, York, UK, 2University Hospital of Malmö, Malmö, Sweden, 3KCI USA, Inc, San Antonio, TX, USA, 4Milliman, Windsor, CT, USA

PDB12
RESOURCE UTILIZATION AND ECONOMIC COST OF CARE BASED ON A RANDOMIZED TRIAL OF V.A.C.® THERAPY IN THE TREATMENT OF DIABETIC FOOT ULCER WOUNDS

Apelqvist J1, Armstrong DG2, Lavery LA3, Boulton AJ4, Keith MS5

1
University Hospital of Malmo, Malmo, Sweden, 2Rosalind Franklin University of Medicine and Science, Chicago, IL, USA, 3Scott & White, Georgetown, TX, USA, 4Manchester Royal Infirmary, Manchester, UK, 5KCI USA, San Antonio, TX, USA

PDB13
COPAYMENT LEVEL AND MEDICATION ADHERENCE IN TYPE 2 DIABETES PATIENTS MANAGED WITH INSULIN ASPART PEN THERAPY

Lee WC
1, Balu S2, Cobden D3, Joshi AV3, Pashos CL2
1
Abt Associates Inc, Bethesda, MD, USA, 2Abt Associates Inc, Lexington, MA, USA, 3Novo Nordisk Inc, Princeton, NJ, USA

PDB14
ECONOMIC OUTCOMES ASSOCIATED WITH SWITCHING TO INSULIN PEN THERAPY IN MEDICAID TYPE 2 DIABETES PATIENTS: A RETROSPECTIVE DATABASE ANALYSIS

Pawaskar MD
1, Camacho F2, Anderson RT2, Cobden D3, Joshi AV3, Balkrishnan R1
1
The Ohio State University College of Pharmacy, Columbus, OH, USA, 2Wake Forest University School of Medicine, Winston Salem, NC, USA, 3Novo Nordisk Inc, Princeton, NJ, USA

PDB15
TREATMENT COSTS ATTRIBUTABLE TO OVERWEIGHT/OBESE IN PATIENTS WITH DIABETES MELLITUS IN THE U.S. ADULT POPULATION

Kim CM
1, Choi IS2, Huang J2, Suh DC2, Barone JA2 
1
Catholic University, Seoul, Suhcho-gu, South Korea, 2Rutgers University, Piscataway, NJ, USA

PDB16
EMERGENCY ROOM CARE FOR DIABETES MELLITUS IN THE UNITED STATES: HOW MUCH DOES IT COST?

Addo-Atuah J, Waters T, White-Means S, Gourley D
University of Tennessee Health Science Center, Memphis, TN, USA

PDB17
DETERMINATION OF HEALTH CARE COSTS INCURRED BY SWEDISH PATIENTS WITH TYPE 2 DIABETES

Ringborg A
1, Stålhammar J2, Martinell M2, Yin D3, Lindgren P1
1
European Health Economics, Stockholm, SE, Sweden, 2Uppsala University, Uppsala, Sweden, 3Merck & Co., Inc, Whitehouse Station, NJ, USA

PDB18
THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN USING UK REAL LIFE DATA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

McEwan P
1, Mehin N2, Tetlow AP3, Sharplin P3
1
Cardiff University, Cardiff, South Glamorgan, UK, 2sanofi-aventis, Paris, France, 3CRC, Cardiff, South Glamorgan, UK

PDB19
THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN USING UK REAL LIFE DATA IN TYPE 1 DIABETES MELLITUS

McEwan P
1, Mehin N2, Tetlow AP3, Sharplin P3
1
Cardiff University, Cardiff, South Glamorgan, UK, 2sanofi-aventis, Paris, France, 3CRC, Cardiff, South Glamorgan, UK

PDB20
COMPARISON OF ROSIGLITAZONE VERSUS PIOGLITAZONE INTRODUCTION AND ASSOCIATED HEALTH CARE UTILIZATION IN TYPE 2 DIABETES MEDICAID ENROLLEES

Balkrishnan R
1, Arondekar B2, Shenolikar R1, Camacho F3, Horblyuk R2, Anderson RT3
1
The Ohio State University College of Pharmacy, Columbus, OH, USA, 2GlaxoSmithKline, Philadelphia, PA, USA, 3Wake Forest University School of Medicine, Winston Salem, NC, USA

Health Care Use & Policy Studies 

PDB21
PRICE AND UTILIZATION OF ORAL ANTI-DIABETIC MEDICATIONS FROM 1991 TO 2005 IN U.S. MEDICAID PROGRAMS

Li X
, Doherty M, Kelton CM, Jing Y, Guo JJ
University of Cincinnati, Cincinnati, OH, USA

PDB22
INFLUENCE OF HEMOGLOBIN A1C TEST RESULT ON DECISION TO INITIATE INSULIN SUPPLEMENTATION IN TYPE 2 DIABETES

Durden ED
, Bizier R, Huse D
Thomson Medstat, Cambridge, MA, USA

PDB23
IMPACT OF PATIENT EDUCATION ON HBA1C REDUCTION IN DIABETIC PATIENTS WITH CONCOMITANT HYPERTENSION

Shaya FT
1, Samant ND1, Saunders E2
1
University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland School of Medicine, Baltimore, MD, USA

Methods & Concepts 

PDB24 - Withdrawn

PDB25
HEALTH STATUS AND QUALITY OF LIFE IN TYPE 2 DIABETES MELLITUS: RELATIONSHIPS IN A CROSS-SECTIONAL STUDY

Sundaram M
, Miller LA, Kavookjian J
West Virginia
University School of Pharmacy, Morgantown, WV, USA

Patient-Reported Outcomes 

PDB26
CAN PATIENTS ACCURATELY RATE THEIR ADHERENCE TO MEDICATIONS?

Nau DP
1, Steinke D1, Elston Lafata J2, Williams LK2, Divine G2, Austin R2, Pladevall M2
1
University of Kentucky, Lexington, KY, USA, 2Henry Ford Health System, Detroit, MI, USA

PDB27
MEDICATION ADHERENCE IN PATIENTS WITH DIABETES DURING THE MEDICARE PART D BENEFIT COVERAGE GAP PERIOD

Prasla K
1, Godley P1, Rascati KL2, Gabrillo E1 
1
Scott and White Health Plan, Temple, TX, USA, 2The University of Texas at Austin, Austin, TX, USA

PDB28
IMPACT OF INITIATING OR CONVERTING TO TREATMENT WITH AN INSULIN ASPART ANALOG PEN ON MEDICATION ADHERENCE IN TYPE 2 DIABETES PATIENTS ON VIAL/SYRINGE INSULIN

Balu S
1, Lee WC2, Cobden D3, Joshi AV3, Pashos CL1
1
Abt Associates Inc, Lexington, MA, USA, 2Abt Associates Inc, Bethesda, MD, USA, 3Novo Nordisk Inc, Princeton, NJ, USA

PDB29
RELATIONSHIP BETWEEN EATING HEALTHY FOODS AND REGULAR EXERCISE AND PHYSICAL HEALTH, MENTAL HEALTH, AND HEALTH STATUS IN TYPE II DIABETICS

Campbell HM
1, Khan N2, Raisch DW1
1
Department of Veterans Affairs Cooperative Studies Program, Albuquerque, NM, USA, 2University of New Mexico, Albuquerque, NM, USA

PDB30
HEALTH RELATED QUALITY OF LIFE ON BODY MASS INDEX FOR PEOPLE WITH TYPE 2 DIABETES IN THE GENERAL ADULT POPULATION IN ENGLAND

Christensen T
1, Hammer M1, Gough S2
1
Novo Nordisk A/S, Bagsværd, Denmark, 2University of Birmingham, Birmingham, UK

PDB31
HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PRIMARY CARE PATIENTS WITH TYPE 2 DIABETES MELLITUS AND DEPRESSION

Shah BM
, Knapp KK
Touro University - CA, Vallejo, CA, USA

PDB32
HEALTH-RELATED QUALITY OF LIFE AND UTILITIES OF RESPONDENTS WITH TYPE 2 DIABETES COMPARED TO THOSE WITH DIFFERING LEVELS OF CARDIOMETABOLIC RISK

Chapman RH1, Fox KM2, Grandy S3
1
ValueMedics Research, Falls Church, VA, USA, 2Strategic Health care Solutions, LLC, Monkton, MD, USA, 3AstraZeneca, Wilmington, DE, USA

PDB33
VALIDATION OF THE 25-ITEM NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE (VFQ-25) IN PATIENTS WITH DIABETIC RETINOPATHY

Rousculp MD1, Matza LS2, Malley K3, Oglesby AK1, Boye KS1

1
Eli Lilly and Company, Indianapolis, IN, USA, 2United BioSource Corporation, Bethesda, MD, USA, 3Malley Research Programming, Inc, Rockville, MD, USA

PDB34
EFFECT OF INSULIN GLARGINE AND NPH INSULIN ON QUALITY OF LIFE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Gupta KS
, Gupta U
Maulana
Azad Medical College, New Delhi, India

PDB35
ESTIMATING HEALTH-RELATED QUALITY OF LIFE FROM HYPOGLYCEMIA ELICITED FROM NON-DIABETIC AND DIABETIC RESPONDENTS IN CANADA

Levy AR1, Christensen T2, Bavinton H1, Tabberer M3, Johnson JA4

1
Oxford Outcomes Ltd, Vancouver, BC, Canada, 2Novo Nordisk A/S, Bagsværd, Denmark, 3Oxford Outcomes Ltd, Oxford, Oxon, UK, 4University of Alberta, Edmonton, AB, Canada

PDB36
DIFFERENCES IN EQ-5D SCORES FOR US AND UK-BASED PREFERENCE SCORING SYSTEMS IN PEOPLE WITH TYPE 2 DIABETES MELLITUS

Sundaram M
1, Johnson JA2, Miller LA1
1
West Virginia University School of Pharmacy, Morgantown, WV, USA, 2Institute of Health Economics, Edmonton, AB, Canada

ENDOCRINE DISORDERS

Patient-Reported Outcomes

PEN1
ESTIMATING THE QALY BENEFITS OF TREATMENT FOR GROWTH HORMONE DEFICIENCY (GHD) IN ADULT PATIENTS: A PRECURSOR TO COST-EFFECTIVENESS ANALYSIS
Koltowska-Haggstrom M1, Jonsson B2, Monson JP3, Kind P4
1KIMS Medical Outcomes, Pfizer Endocrine Care, Sollentuna, Sweden, 2Uppsala University, Uppsala, Sweden, 3St Bartholomew's Hospital, Queen Mary University of London, London, UK, 4Outcomes Research Group, Centre for Health Economics, University of York, York, UK

MENTAL HEALTH

Clinical Outcomes Studies

PMH1
CHANGES IN COMORBIDITIES, MEDICATION USE AND TREATMENT COSTS AFTER DIAGNOSIS OF GENERALIZED ANXIETY DISORDER
Swindle R, Ye W, Zhao Z, Zhu B
Eli Lilly and Company, Indianapolis, IN, USA

PMH2
DIVALPROEX SODIUM VERSUS VALPROIC ACID: DRUG UTILIZATION PATTERNS, PERSISTENCE RATES, AND PREDICTORS OF HOSPITALIZATION AMONG VA PATIENTS DIAGNOSED WITH BIPOLAR DISORDER
Iqbal SU1, Cunningham F2, Lee A3, Wang S4, Hamed A5, Ren X6, Miller D6, Kazis L1
1Center for the Assessment of Pharmaceutical Practices (CAPP), Boston University School of Public Health, Boston, MA, USA, 2Pharmacy Benefits Management , Veterans Affairs Medical Center (VAMC), Hines, IL, USA, 3Center for Health Quality Outcomes & Economic Research (CHQOER), Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, USA, 4Center for Health Quality Outcomes and Economic Research (CHQOER), Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, USA, 5Center for the Assessment of Pharmaceutical Practices (CAPP), Boston University School, Boston, MA, USA, 6Center for Health Quality, Outcomes, and Economic Research (CHQOER), Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, USA

PMH3
ANTIDEPRESSANT PROPHYLAXIS FOR POST-STROKE DEPRESSION: A META-ANALYSIS
Chen Y1, Patel NC1, Guo JJ1, Zhan S2
1University of Cincinnati, Cincinnati, OH, USA, 2Peking Univeristy, Beijing, Beijing, China

PMH4
ADVERSE EVENT PROFILE ASSOCIATED WITH OFF-LABEL USE OF ANTIPSYCHOTIC MEDICATIONS
Abbass I, Chen H
University of Houston, Houston, TX, USA

PMH5
A COMPARISON OF TREATMENT-EMERGENT DIABETES AMONG ATYPICAL AND TYPICAL ANTIPSYCHOTIC USERS: USING A BIVARIATE PROBIT MODEL
Stafkey-Mailey DR, McCombs JS, Hay JW
University of Southern California, Los Angeles, CA, USA

PMH6 - WITHDRAWN

PMH7
SUICIDALITY AND ANTIDEPRESSANTS USE IN CHILDREN AND ADOLESCENTS
Yuan Y1, Carlson A2, Andis G3
1University of Minnesota, Minneapolis, MN, USA, 2Data Intelligence Consultants, LLC, Eden Prairie, MN, USA, 3Medica Health Plans, Minnetonka, MN, USA

Cost Studies

PMH8
FORECASTING U.S. MEDICAID PROGRAM EXPENDITURE ON ANTIDEPRESSANT DRUGS
Ferrand YB, Kelton CM, Levy MS, Guo JJ
University of Cincinnati, Cincinnati, OH, USA

PMH9
NET BENEFIT ANALYSIS OF DIVALPROEX SODIUM EXTENDED-RELEASE COMPARED TO VALPROIC ACID IN THE TREATMENT OF BIPOLAR DISORDER
Gupta SR1, Schumock GT1, Walton SM1, Cramer JA2
1University of Illinois at Chicago, Chicago, IL, USA, 2Yale University School of Medicine, West Haven, CT, USA

PMH10
COST-EFFECTIVINESS ANALYSIS OF LONG ACTING MICROSPHERES OF RISPERIDONE ( RISPERDAL CONSTA) IN THE TREATMENT OF SCHIZOPHRENIA IN MEXICO
Vazquez V
Janssen-Cilag, Mexico, Mexico, Mexico

PMH11
MEDICATION USE PATTERNS AND COSTS ASSOCIATED WITH ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF BIPOLAR DISORDER
Zhu B, Kulkarni P, Stensland M, Ascher-Svanum H
Eli Lilly and Company, Indianapolis, IN, USA

PMH12
DEPRESSED INDIVIDUALS WITH MUSCULOSKELETAL CHRONIC PAIN AND HEADACHE SHOW HIGHER HEALTH CARE UTILIZATION AND COSTS
Iyer RG, Fensterheim LE, Berger JE, Dodds MM, Weston NK
Caremark Inc, Northbrook, IL, USA

PMH13
COST-EFFECTIVENESS ANALYSIS OF SINGLE-DOSE EXTENDED RELEASE METHYLPHENIDATE (CONCERTA®) VS. ATOMOXETINE AND SHORT-ACTION METHYLPHENIDATE, FOR THE MANAGEMENT OF ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY IN MEXICO
Vazquez V
Janssen-Cilag, Mexico, Mexico

PMH14
COST-EFFECTIVENESS ANALYSIS OF GALANTAMINE (REMINYL ER) IN THE TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEMIER'S TYPE IN MEXICO
Agramonte J
Janssen-Cilag,SA de CV, Mexico City, Mexico

PMH15 - Withdrawn

PMH16
PREDICTORS OF HIGH COSTS FOR GENERALIZED ANXIETY DISORDER WITH OR WITHOUT PAIN
Zhu B, Zhao Z, Ye W, Swindle R
Eli Lilly and Company, Indianapolis, IN, USA

PMH17
TREATMENT COSTS OF COMORBID GENERALIZED ANXIETY DISORDER, DEPRESSION AND PAIN
Zhao Z, Zhu B, Ye W, Swindle R
Eli Lilly and Company, Indianapolis, IN, USA

PMH18
INCREMENTAL MEDICAID EXPENDITURES ASSOCIATED WITH DEMENTIA
Modi A1, Bharmal M2, Dedhiya S1, Craig B1, Weiner M3, Rosenman M4, Sands L5, Thomas III J6
1Purdue University, West Lafayette, IN, USA, 2Quintiles Transnational Corporation, Falls Church, VA, USA, 3Indiana University, Indiana University Center for Aging Research and Regenstrief Institute Inc, Indianapolis, IN, USA, 4Indiana University and Regenstrief Institute Inc, Indianapolis, IN, USA, 5Purdue University and Regenstrief Center for Health care Engineering, West Lafayette, IN, USA, 6Purdue University and Regenstrief center for Health care Engineering, West Lafayette, IN, USA

PMH19
A COMPARISON OF TOTAL DIRECT MEDICAL COSTS TO MANAGED CARE OF ESCITALOPRAM VERSUS VENLAFAXINE XR TREATMENT IN MAJOR DEPRESSIVE DISORDER
Erder MH, Wang C, Jonas JM
Forest Research Institute, Jersey City, NJ, USA

PMH20
THE ECONOMIC COSTS TO MANAGED CARE ORGANIZATIONS OF EXCESS MD WITHDRAWAL FROM DULOXETINE TREATMENT: AN OPPORTUNITY COSTS MODEL
Erder MH, Wang C, Jonas JM
Forest Research Institute, Jersey City, NJ, USA

PMH21
ANALYSIS OF DRUG TREATMENT PATTERNS, SERVICE USE AND COSTS ASSOCIATED WITH SPECIFIC PHARMACOLOGICAL TREATMENTS FOR MAJOR DEPRSSIVE DISORDER
Becker MA1, Jones M2, Patel T1
1University of South Florida, Tampa, FL, USA, 2Eli Lilly and Company, Indianopolis, IN, USA

PMH22
HEALTH CARE COSTS AND RESOURCE USE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: A COMPARISON BETWEEN ESCITALOPRAM AND OTHER ANTIDEPRESSANTS
Wu E1, Yang E1, Greenberg P1, Erder H2, Yu AP1, Buesing M1
1Analysis Group, Inc, Boston, MA, USA, 2Forest Research Institute, Jersey City, NJ, USA

PMH23
ECONOMIC EVALUATION OF LONG ACTING TREATMENTS FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN THE MILITARY HEALTH SYSTEM
Devine JW, Moore E, Tiller KW, Trice S, Meade DJ, Lawrence JB
Department of Defense Pharmacoeconomic Center, Fort Sam Houston, TX, USA

PMH24
36-MONTH COST-UTILITY ANALYSIS OF ANTIPSYCHOTIC TREATMENTS IN PATIENTS WITH SCHIZOPHRENIA IN THE PAN-EUROPEAN SOHO (SCHIZOPHRENIA OUTPATIENT HEALTH OUTCOMES) STUDY
Windmeijer F1, Brown J2, Novick D2, Hong J3, Knapp M3, Kontodimas S2, Ratcliffe M2
1University of Bristol, Bristol, UK, 2Eli Lilly and Company Limited, Windlesham, Surrey, UK, 3London School of Economics, London, UK

Health Care Use & Policy Studies

PMH25
PREDICTORS OF BIPOLAR DISORDER IN PATIENTS DIAGNOSED WITH MAJOR DEPRESSION IN A PRIVATELY INSURED POPULATION
Kamat S1, Rajagopalan K2, Pethick N2, Willey VJ1
1HealthCore, Inc, Wilmington, DE, USA, 2AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

PMH26
ACCESS TO ILLICT DRUGS: POLICY IMPLICATIONS FROM THE 2003 NATIONAL SURVEY
Lee D
Cleveland State University, Cleveland, OH, USA

PMH27
STIMULANT UTILIZATION IN CHILDREN UNDER A STATE EMPLOYEES BENEFIT PROGRAM
Gardner SF, Stowe CD
University of Arkansas for Medical Sciences, Little Rock, AR, USA

PMH28 - Withdrawn

PMH29
ECONOMIC BURDEN OF ALCOHOLISM AND ALCOHOL ABUSE IN A US MANAGED-CARE SETTING
Weycker D1, Erder H2, Edelsberg J1, Holder H3, Oster G1
1Policy Analysis Inc. (PAI), Brookline, MA, USA, 2Forest Research Institute, Jersey City, NJ, USA, 3Prevention Research Center, Berkeley, CA, USA

PMH30
HEALTH CARE BURDEN OF PATIENTS WITH ALCOHOL DEPENDENCE SYNDROME
Weycker D1, Erder MH2, Edelsberg J1, Holder H3, Sofrygin O1, Oster G1
1Policy Analysis Inc. (PAI), Brookline, MA, USA, 2Forest Research Institute, Jersey City, NJ, USA, 3Prevention Research Center, Berkeley, CA, USA

PMH31
DRUG COST DEVELOPMENT OF CITALOPRAM AND FLUOXETINE FOLLOWING THE INTRODUCTION OF GENERIC SUBSTITUTION IN FINLAND
Aalto-Setälä VI
University of Helsinki, Helsinki, Finland

PMH32
HEALTH SERVICE AND PRESCRIPTION DRUG USE AND COSTS AMONG HISPANIC AND NON-HISPANIC CAUCASIAN SUBJECTS WITH ADHD
Riedel AA1, Cao F2, Zhang H3
1i3Innovus, Eden Prairie, MN, USA, 2i3 Innovus, Reston, VA, USA, 3McNeil Pediatrics Division of McNeil-PPC Inc, Fort Washington, PA, USA

PMH33
PROFILING UTILIZATION PATTERNS OF ANTIPSYCHOTICS AMONG PATIENTS WITH BIPOLAR DISORDER: A CLAIMS DATA ANALYSIS
Hassan M1, Madhavan SS2, Kalsekar ID3, Rajagopalan K1, Islam S2, Kavookjian J2, Miller LA2, Makela EH2
1AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA, 2West Virginia University, Morgantown, WV, USA, 3Butler University, Indianapolis, IN, USA

PMH34
PHARMACOLOGIC TREATMENT OF GENERALIZED ANXIETY DISORDER WITH COMORBID DEPRESSION AND PAIN CONDITIONS
Ye W, Zhao Z, Zhu B, Swindle R
Eli Lilly and Company, Indianapolis, IN, USA

PMH35
TREATMENT INITIATION WITH ATOMOXETINE VS. STIMULANTS FOR ADULTS WITH ADHD IN MEDICAID SETTINGS
Ye W1, Van Brunt D1, Pohl G1, Johnston J1, Chang LL2
1Eli Lilly and Company, Indianapolis, IN, USA, 2IMS, Plymouth Meeting, PA, USA

Methods & Concepts

PMH36
DISEASE PROGRESSION IN ALZHEIMER'S DISEASE PATIENTS TREATED WITH A CHOLINESTERASE INHIBITOR IN CLINICAL PRACTICE
Gustavsson A1, Parmler J2, Ganguly R3, Minthon L4, Jönsson L5
1European Health Economics, Stockholm, Sweden, 2Stockholm School of Economics, Stockholm, Sweden, 3GlaxoSmithKline, Research Triangle Park, NC, USA, 4Malmö University Hospital, Malmö, Sweden, 5European Health Economics, London, UK

PMH37
TREATMENT PERSISTENCE AND COMPLIANCE WITH GALANTAMINE ER
Yeaw J1, Crivera C2, Rupnow M2, Ollendorf D1
1PharMetrics, a unit of IMS, Watertown, MA, USA, 2Ortho-McNeil Janssen Scientific Affairs, L.L.C, Titusville, NJ, USA

PMH38
ASSESSING PERSISTENCE OF ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA: USING THE DATA FROM PENNSYLVANIA MEDICAID TO UNDERSTAND THE CHALLENGES
Zhu B, Ball DE, Phillips GA, Faries D, Zhao Z, Ascher-Svanum H
Eli Lilly and Company, Indianapolis, IN, USA

PMH39
A MULTI-DOMAIN MICRO-SIMULATION ECONOMIC MODELING FRAMEWORK IN ALZHEIMER'S DISEASE
Jönsson L1, Gustavsson A2, Ganguly R3
1European Health Economics, London, UK, 2European Health Economics, Stockholm, Sweden, 3GlaxoSmithKline, Research Triangle Park, NC, USA

PMH40
12-MONTH TREATMENT DISCONTINUATION RATES IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG ACTING INJECTION (RLAI): INTERIM RESULTS FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY PROJECT CONDUCTED IN SPAIN, AUSTRALIA AND BELGIUM
Olivares JM1, Emmerson B2, Peuskens J3, Diels J4, Caleo S5, Povey M6, Lam A7
1Servicio de Psiquiatria Hospital, Vigo, Spain, 2Royal Brisbane and Women's Hospital, Herston, Queensland, Australia, 3Universitair Psychiatrisch Centrum, KUL Leuven, Leuven, Belgium, 4Janssen Pharmaceutica, Beerse, Belgium, 5Janssen Pharmaceutica N.V, Beerse, Belgium, 6SGS Life Science Services Belgium, Wavre, Belgium, 7Johnson and Johnson Pharmaceutical Services, Toronto, ON, Canada

PMH41
RISPERIDONE LONG ACTING INJECTION (RLAI) IN THE TREATMENT OF EARLY VERSUS LATE DIAGNOSIS PATIENTS WITH SCHIZOPHRENIA: INTERIM RESULTS FROM OBSERVATIONAL STUDIES CONDUCTED IN SPAIN, AUSTRALIA AND BELGIUM
Olivares JM1, Lambert TJR2, Peuskens J3, Caleo S4, Povey M5, Lam A6
1Servicio de Psiquiatria Hospital, Vigo, Spain, 2The University of Melbourne, Melbourne, Victoria, Australia, 3Universitair Psychiatrisch Centrum, KUL Leuven, Leuven, Belgium, 4Janssen Pharmaceutica N.V, Beerse, Belgium, 5SGS Life Science Services Belgium, Wavre, Belgium, 6Johnson and Johnson Pharmaceutical Services, Toronto, ON, Canada

PMH42
IMPACT OF ALTERNATIVE CENSORING SPECIFICATIONS ON TIME-TO-EVENT ANALYSES COMPARING ALTERNATIVE MEDICATIONS
McCombs JS, Stafkey-Mailey DR
University of Southern California, Los Angeles, CA, USA

Patient-Reported Outcomes

PMH43
SWITCHING OF ANTIPSYCHOTICS AMONG STABLE AND UNSTABLE SCHIZOPHRENIA PATIENTS
Zhu B, Ascher-Svanum H, Johnstone B, Faries D
Eli Lilly and Company, Indianapolis, IN, USA

PMH44
THE PREDICTIVE VALIDITY OF DIFFERENT ADHERENCE MEASURES USING ADMINISTRATIVE CLAIMS DATA
Karve SJ, Martin BC
University of Arkansas for Medical Sciences, Little Rock, AR, USA

PMH45
SOCIODEMOGRAPHIC AND CLINICAL CORRELATES OF UTILITY SCORES IN ALZHEIMERS DISEASE
Rosenheck RA1, Miller EA2, Schneider L3, Zbrozek A4
1Yale Medical School, West Haven, CT, CT, USA, 2Brown University, Providence, RI, USA, 3University of Southern California Keck School of Medicine, Los Angeles, CA, USA, 4Wyeth Research, Philadelphia, PA, USA

PMH46
NOVEL USE OF A TELEPHONE BASED INTERACTIVE VOICE RESPONSE SYSTEM TO IMPROVE DATA COLLECTION
Pierce J, Wenzel K
ClinPhone, East Windsor, NJ, USA

PMH47
THE EFFECTS OF PATIENT TYPE ON PHYSICAL AND MENTAL HEALTH OF CAREGIVERS IN FRANCE, GERMANY, ITALY, SPAIN AND UK
Kannan H, Bolge SC
Consumer Health Sciences, Princeton, NJ, USA

PMH48
PREFERENCE AND WILLINGNESS-TO-PAY STUDY TO ASSESS THE VALUE OF ATOMOXETINE USING DISCRETE CHOICE ANALYSIS: UK PARENTS PERSPECTIVE
Cottrell S1, Allen E1, Pascoe K1, Sullivan T1, LeReun C2, Brown J3, Lorenzo M3, Aristides M1
1IMS HEOR, London, UK, 2IMS HEOR, Sydney, Australia, 3Eli Lilly and Company Limited, Windlesham, Surrey, UK

NEUROLOGICAL DISORDERS

Clinical Outcomes Studies

PND1
ASSESSING THE NET CLINICAL BENEFIT AND ABSOLUTE RISK REDUCTION OF DISEASE MODIFYING DRUGS IN RELAPSING REMITTING MULTIPLE SCLEROSIS
AL-Sabbagh A1, Bennett R2, Glanzman R3
1Serono, Rockland, MA, USA, 2Serono, Inc, Rockland, MA, USA, 3Pfizer, New York, NY, USA

PND2
SAFETY AND IMMUNOGENICITY OF REBIF® NEW FORMULATION (RNF) A NEW SUBCUTANEOUS FORMULATION OF INTERFERON BETA-1A 44 MCG THREE TIMES WEEKLY: 1-YEAR RESULTS OF A PHASE IIIB STUDY IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
Simsarian J1, AL-Sabbagh A2, Bennett R2, Stubinski B3, Pardo G4
1Neurology Center of Fairfax, Fairfax, VA, USA, 2Serono, Inc, Rockland, MA, USA, 3Serono, Inc, Geneva, Switzerland, 4Multiple Sclerosis Center of Oklahoma, Oklahoma City, OK, USA

Cost Studies

PND3
THE BUDGETARY IMPACT OF THE UTILIZATION OF NATALIZUMAB FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS
Chiao E, Meyer K
Xcenda, Princeton, NJ, USA

PND4
RESOURCE UTILIZATION PATTERNS WITH TOPIRAMATE FOR MIGRAINE PREVENTION IN THE MANAGED CARE SETTING
Yaldo AZ1, Wertz D2, Rupnow MF3, Quimbo R4
1Ortho-McNeil Janssen Scientific Affairs, Titusville, NJ, USA, 2Healthcore, Inc, Wilmington, DE, USA, 3Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 4HealthCore, Inc, Wilmington, DE, USA

PND5
DOES SPECIALTY CARE OF SPINA BIFIDA PATIENTS INFLUENCE COST OF CARE?
Doctor JN1, Connell F2, Larison C2, Cardenas D3, Topolski T4
1University of Southern California, Los Angeles, CA, USA, 2University of Washington, Seattle, WA, USA, 3University of Miami, Miami, FL, USA, 4Center for Disability and Policy Research at the University of Washington, Seattle, WA, USA

PND6
COST-EFFECTIVENESS OF SCREENING FOR COGNITIVE IMPAIRMENT IN OLDER POPULATIONS: IMPLICATIONS FOR ALZHEIMER'S DISEASE CARE.
Neumann PJ1, Cohen JT1, Zhang B2, Fillit HM3
1Tufts-New England Medical Center, Boston, MA, USA, 2Boston Health Economics, Waltham, MA, USA, 3Institute for the Study of Aging, New York, NY, USA

PND7
PHARMACOECONOMIC ANALYSIS OF ANTIEPILEPTIC DRUGS IN THE TREATMENT OF THE IDIOPATHIC GENERALIZED EPILEPSIES
Polivanov V, Kulikov A
Moscow Medical Academy, Moscow, Russia

PND8
COST-EFFECTIVENESS OF PREGABALIN AND OTHER ADD-ON ANTIEPILEPTIC DRUG THERAPIES IN PATIENTS WITH REFRACTORY PARTIAL EPILEPSY IN ARGENTINA
Aiello EC1, Thomson A2, Vera-Llonch M3, Elorza P1, Sadosky A4, Oster G3
1Pfizer Argentina, Buenos Aires, -, Argentina, 2Hospital Francés, Buenos Aires, -, Argentina, 3PAI, Brookline, MA, USA, 4Pfizer, Inc, New York, NY, USA

PND9
THE COST-EFFECTIVENESS OF NATALIZUMAB IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
Meyer K, Chiao E
Xcenda, Princeton, NJ, USA

PND10
AN ANALYSIS OF THE HEALTH AND PRODUCTIVITY BURDEN OF INSOMNIA AND ITS TREATMENT
Hawkins K1, Treglia M2, Wang S3, Healey P4, Mendelson W5, Harnett J4
1IMS Health, Brooklyn, MI, USA, 2Pfizer Inc, Groton, CT, USA, 3Thomson-Medstat, Cambridge, MA, USA, 4Pfizer Inc, New York, NY, USA, 5The University of Chicago, Galveston, TX, USA

PND11
LIFETIME CLINICAL AND ECONOMIC CONSEQUENCES OF CHANGES IN BODY WEIGHT ASSOCIATED WITH MIGRAINE HEADACHE PROPHYLAXIS WITH TOPIRAMATE VERSUS AMITRIPTYLINE
Vera-Llonch M1, Rupnow MF2, Gagne JJ2, Siu T1, Oster G1
1PAI, Brookline, MA, USA, 2Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA

PND12
IMPACT OF RELAPSES ON TOTAL COSTS OF CARE FOR PATIENTS WITH MULTIPLE SCLEROSIS
Bennett R1, Cisternas M2, Foreman A2, Miller DP2, AL-Sabbagh A3
1Serono, Inc, Rockland, MA, USA, 2Ovation Research Group, San Francisco, CA, USA, 3Serono, Rockland, MA, USA

PND13
HEALTH CARE COSTS AND UTILIZATION FOR ALZHEIMER'S DISEASE PATIENTS
Zhao Y1, Kuo TC2, Weir S3, Kramer MS2, Ash AS4
1Eli Lilly and Company, Indianapolis, IN, USA, 2DxCG, Inc, Boston, MA, USA, 3University of Massachusetts Medical School, Shrewsbury, MA, USA, 4Boston University, Bosotn, MA, USA

PND14
ECONOMIC CONSEQUENCES OF THERAPEUTIC ALTERATION IN THE MANAGEMENT OF INSOMNIA
Pollack M1, Joish V2, Cziraky MJ1
1HealthCore, Inc, Wilmington, DE, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA

PND15
ECONOMIC CONSEQUENCES OF GENERIC SUBSTITUTION FOR ANTIEPILEPTIC MEDICATION: THE CASE OF LAMOTRIGINE
Duh M1, Andermann F2, Paradis PE3, Weiner J1, Manjunath R4, Crémieux PY1
1Analysis Group, Inc, Boston, MA, USA, 2Montreal Neurological Institute and Hospital, Montreal, QC, Canada, 3Groupe d'analyse, Ltd, Montreal, QC, Canada, 4GlaxoSmithKline, RTP, NC, USA

PND16
ASSOCIATION OF LONG-TERM MIGRAINE PREVENTIVE MEDICATION USE AND RESOURCE UTILIZATION/PRODUCTIVITY LOSS: RESULTS FROM THE AMERICAN MIGRAINE PREVALENCE AND PREVENTION (AAMP) STUDY
Munakata J1, Hazard E1, Tierce JC1, Rupnow M2, Serrano D3, Reed M3, Lipton R4
1ValueMedics Research, LLC, Falls Church, VA, USA, 2Ortho-McNeil Janssen Scientific Affairs, L.L.C, Titusville, NJ, USA, 3Vedanta Associates, Chapel Hill, NC, USA, 4Albert Einstein College of Medicine, Bronx, NY, USA

Health Care Use & Policy Studies

PND17
PREVALENCE OF NON-ADHERENCE TO PARKINSON'S DISEASE MEDICATIONS AND ITS IMPACT ON SYMPTOM PROGRESSION IN A MEDICARE POPULATION
Kulkarni AS1, Edin HM2, Kirsch J3, Balkrishnan R1
1The Ohio State University College of Pharmacy, Columbus, OH, USA, 2GlaxoSmithkline, Research Triangle Park, NC, USA, 3GlaxoSmithkline, Greenford, Middlesex, UK

PND18
DETERMINANTS OF EMERGENCY DEPARTMENT UTILIZATION FOR MIGRAINE CARE
Kwong WJ
University of Georgia, Athens, GA, USA

PND19
DEVELOPING A MIGRAINE QUALITY OF CARE MEASUREMENT SET
Leas B1, Gagne JJ2, Goldfarb NI1, Rupnow MF2, Lofland JH1, Hopkins MM3, Nash D1, Silberstein SD3
1Thomas Jefferson University, Philadelphia, PA, USA, 2Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 3Thomas Jefferson University Hospital, Philadelphia, PA, USA

PND20
UNDERSTANDING LIMITATIONS OF PATIENT REPORTED CLINICAL OUTCOMES IN LUPUS
Wilke CT1, Jolly M2, Khandelwal S3, Rodby R2, Block JA3, Pickard AS4
1University of Illinois at Chicago, Chicago, IL, USA, 2Rush University Medical Center, Chicago, IL, USA, 3Rush Medical University Medical Center, Chicago, IL, USA, 4College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA

PND21
PRODUCT ENHANCEMENTS DECREASE THE INCIDENCE OF INJECTION SITE REACTIONS AND PAIN RESULTING IN IMPROVED ADHERENCE TO THERAPY IN PATIENTS WITH MULTIPLE SCLEROSIS
Scanzillo J1, Bennett R1, Biancucci P1, Divan V2, Sherman S1, AL-Sabbagh A3
1Serono, Inc, Rockland, MA, USA, 2Pfizer, New York, NY, USA, 3Serono, Rockland, MA, USA

Methods & Concepts

PND22
IMPLICATIONS OF COMORBIDITY ON COSTS FOR PATIENTS WITH ALZHEIMER'S DISEASE
Kuo TC1, Zhao Y2, Weir S3, Kramer MS1, Ash AS4
1DxCG, Inc, Boston, MA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3University of Massachusetts Medical School, Shrewsbury, MA, USA, 4Boston University, Bosotn, MA, USA

PND23
PSYCHOMETRIC EVALUATION OF FIVE MIGRAINE SPECIFIC HEALTH RELATED QUALITY OF LIFE INSTRUMENTS
Ramakrishnan S, Franic D
University of Georgia, Athens, GA, USA

Patient-Reported Outcomes

PND24
MEDICATION SIDE-EFFECTS AND ADHERENCE AMONG PATIENTS WITH MULTIPLE SCLEROSIS
Farris K1, Chao J2, Fielding S3, Warren J4
1University of Iowa, Iowa City, IA, USA, 2sanofi-aventis, Bridgewater, NJ, USA, 3Children's Institute, Rochester, NY, USA, 4Harris Interactive, Rochester, NY, USA

PND25
A REVIEW OF HEALTH RELATED QUALITY OF LIFE INSTRUMENTS USED IN CHILDREN AND ADOLESCENTS WITH EPILEPSY
Rane PB, Kamal KM
Duquesne University, Pittsburgh, PA, USA

PND26
MEASUREMENT OF QUALITY OF LIFE IN RESTLESS LEGS SYNDROME
Naik S, Kamal KM
Duquesne University, Pittsburgh, PA, USA

PND27
DETECTION OF DIFFERENTIAL ITEM FUNCTIONING BETWEEN ENGLISH AND CHINESE VERSIONS OF THE PDQ-8
Luo N1, Xie F1, Au WL2, Lau PN2, Tan LC2
1National University of Singapore, Singapore, Singapore, 2National Neuroscience Institute, Singapore, Singapore

PND28
PSYCHOMETRIC EVALUATION OF OBSTRUCTIVE SLEEP APNEA SPECIFIC HEALTH RELATED QUALITY OF LIFE INSTRUMENTS
Williams C, Franic D
University of Georgia, Athens, GA, USA

PND29
THE IMPACT OF RESTLESS LEGS SYNDROME ON VARIOUS DIMENSIONS OF LIFE: RESULTS OF A WEB-BASED PATIENT SURVEY
McLeod LD1, Fehnel SE1, Zografos LJ1, Sander S2, Curtice TG2, Shah H2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA

PND30
COMORBIDITIES, ECONOMIC AND HUMANISTIC FACTORS ASSOCIATED WITH MIGRAINE: A PROPENSITY SCORE ANALYSIS OF NATIONAL SURVEY DATA
Gagne JJ1, Bolge SC2, Mills DL2, Rupnow MF1
1Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 2Consumer Health Sciences, Princeton, NJ, USA

PND31
THE IMPACT OF CHRONIC INSOMNIA ON PRODUCTIVITY IN THE US, FRANCE, AND JAPAN
Martin M1, Cure S1, Gilloteau I2, Walsh J3, Leger D4, Uchiyama M5, Kobayashi M6, Morin C7
1i3 Innovus, Uxbridge, Middlesex, UK, 2Sanofi-Aventis, Bagneux, France, 3Sleep Medicine and Research Centre, St. Lukes Hospital, St Louis, MO, USA, 4Centre du Sommeil et de la Vigilance de l’Hôtel Dieu, Paris, France, 5Nihon University School of Medicine, Tokyo, Japan, 6Crecon Research and Consulting Inc, Shibuya-ku, Tokyo, Japan, 7Laval University, Quebec city, Quebec, Canada

OSTEOPOROSIS & INJURIES

Clinical Outcomes Studies

POI1
THE CONNECTION BETWEEN 5 YEARS MORTALITY FOLLOWING FEMORAL NECK FRACTURE AND ITS RISK FACTORS
Sebestyén A1, Boncz I1, Sándor J2, Betlehem J2, Oláh A2, Nyárády J2
1National Health Insurance Fund Administration, Budapest, Hungary, 2University of Pécs, Pécs, Hungary

POI2
KAPLAN-MEIER SURVIVAL ANALYSIS OF PATIENTS WITH DISPLACED AND NON-DISPLACED FEMORAL NECK FRACTURE OVER 60
Sebestyén A1, Boncz I1, Oláh A2, Betlehem J2, Nyárády J2
1National Health Insurance Fund Administration, Budapest, Hungary, 2University of Pécs, Pécs, Hungary

Cost Studies

POI3
A COST-EFFECTIVENESS ANALYSIS OF RHBMP-2 IN SPINE FUSION SURGERY IN SWEDEN AND DENMARK
Chhabra A1, Nicklasson L2, Greenberg D3, Alt V4
1Medtronic Europe Sarl, Tolochenaz, Switzerland, 2Medtronic AB, Kista, Sweden, Sweden, 3Ben-Gurion University of the Negev, Beer-Sheva, Israel, 4University Hospital Giessen-Marburg , Brackenheim, Germany

POI4
INPATIENT COSTS AND OUTCOMES ASSOCIATED WITH TRAUMATIC INJURY IN THE UNITED STATES BY INJURY SEVERITY AND TRAUMA CENTER DESIGNATION
Candrilli SD1, Davis KL1, Mitra D1, Tortella BJ2, Joshi AV2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novo Nordisk, Inc, Princeton, NJ, USA

Health Care Use & Policy Studies

POI5 - Withdrawn

Patient-Reported Outcomes

POI6
WOMEN TREATED WITH MONTHLY IBANDRONATE DEMONSTRATE IMPROVED PERSISTENCE VERSUS WEEKLY BISPHOSPHONATES
Cramer JA1, Sunyecz JA2, Derman R3, Harley C4, Poston S5, Barr CE6
1Yale University School of Medicine, West Haven, CT, USA, 2Laurel Highlands Ob/Gyn, P.C, Hopwood, PA, USA, 3University of Missouri-Kansas City, Kansas City, MO, USA, 4i3 Innovus, Eden Prairie, MN, USA, 5GlaxoSmithKline, Research Triangle Park, NC, USA, 6Roche Pharmaceuticals, Nutley, NJ, USA

POI7
WOMEN ARE MORE PERSISTENT WITH MONTHLY IBANDRONATE VS. WEEKLY BISPHOSPHONATES: RESULTS FROM A RETROSPECTIVE DATABASE
Cramer JA1, Silverman S2, Cziraky MJ3, Barr CE4, Poston S5
1Yale University School of Medicine, West Haven, CT, USA, 2Cedars-Sinai Medical Center/UCLA, Beverly Hills, CA, USA, 3HealthCore, Inc, Wilmington, DE, USA, 4Roche Pharmaceuticals, Nutley, NJ, USA, 5GlaxoSmithKline, Research Triangle Park, NC, USA

POI8
CAN THE SF-36 PHYSICAL FUNCTION SCALE CAPTURE FUNCTIONAL OUTCOMES DURING RECOVERY FROM TRAUMATIC INJURY? A REVIEW OF THE LITERATURE
Vernon MK1, Murray L1, Mannix S1, Leidy NK1, Kelly KM2, Mody S2
1United BioSource Corporation, Bethesda, MD, USA, 2Ortho-Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA

SKIN

Cost Studies

PSK1
COST EFFECTIVENESS OF THE USE OF INFLIXIMAB COMPARED TO OTHER BIOLOGICAL AGENTS (BA) IN THE SYSTEMIC TREATMENT OF MODERATE TO SEVERE PSORIASIS
Fonseca M, Araujo G
Axia.Bio Consulting, São Paulo, Brazil

PSK2
THE HEALTH CARE AND WORK LOSS COSTS ASSOCIATED WITH ATOPIC DERMATITIS
Duh MS1, Fowler JF2, Rovba L1, Buteau S1, Pinheiro L1, Lobo F3, Sung J3, Doyle JJ3, Mallett D4, Kosicki G1
1Analysis Group, Inc, Boston, MA, USA, 2University of Louisville, Louisville, KY, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4Ingenix Employer Solutions, New Haven, CT, USA

PSK3
THE DIRECT AND INDIRECT COST BURDEN ASSOCIATED WITH SEBORRHEIC DERMATITIS
Duh MS1, Fowler JF2, Rovba L1, Buteau S1, Pinheiro L1, Lobo F3, Sung J3, Doyle JJ3, Mallett D4, Kosicki G1
1Analysis Group, Inc, Boston, MA, USA, 2University of Louisville, Louisville, KY, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4Ingenix Employer Solutions, New Haven, CT, USA

PSK4
FREQUENCY AND COST CONSEQUENCES ASSOCIATED WITH FAILURE OF MUPIROCIN AMONG UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS (USSSI)
Meissner BL1, Burch P S2, Cantrell CR2
1Xcenda, Palm Harbor, FL, USA, 2GlaxoSmithKline, Research Triangle Park, NC, USA

Health Care Use & Policy Studies

PSK5
QUALITY OF DERMATOLOGIC CARE DELIVERED BY PHYSICIAN ASSISTANTS: AN ANALYSIS OF CLOTRIMAZOLE/BETAMETHASONE PROPIONATE PRESCRIPTIONS
Satyaprakash A1, Jayawant SS2, Feldman SR1, Balkrishnan R2
1Wake Forest University School of Medicine, Winston Salem, NC, USA, 2The Ohio State University College of Pharmacy, Columbus, OH, USA

PSK6
THE IMPACT OF PSORIASIS ON HEALTH CARE COSTS AND WORK LOSS
Duh MS1, Fowler JF2, Rovba L1, Buteau S1, Pinheiro L1, Lobo F3, Sung J3, Doyle JJ3, Mallett D4, Kosicki G1
1Analysis Group, Inc, Boston, MA, USA, 2University of Louisville, Louisville, KY, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4Ingenix Employer Solutions, New Haven, CT, USA

SMOKING

Cost Studies

PSM1
A LONG TERM COST–EFFECTIVENESS ANALYSIS MODEL FOR SMOKING CESSATION IN MEXICO
Mould-Quevedo J, Saenz-Montanez J, Davila-Loaiza G
Pfizer Mexico, Mexico City, Mexico

PSM2
THE COST UTILITY OF VARENICLINE IN SMOKING CESSATION HEALTH PROGRAMMES IN SWEDEN
Bolin K1, Gilljam H2, Mörk AC3, Lindgren B1
1Lund University Centre for Health Economics, Lund, Sweden, 2Centre for Tobacco Prevention, Stockholm, Sweden, 3Pfizer AB, Sollentuna, Sweden

Methods & Concepts

PSM3
ESTIMATING THE INCIDENCE AND PREVALENCE OF SMOKING RELATED MORBIDITIES USING PROXY VALUES
Howard PA1, Knight CJ1, Baker CL2
1Heron Evidence Development Ltd, Letchworth, Hertfordshire, UK, 2Pfizer Inc, New York, NY, USA

Patient-Reported Outcomes

PSM4
CONSUMER PERCEPTION OF SELF-AID MATERIALS IN OVER-THE-COUNTER NICOTINE PATCH
Shi CW, Zhu SH, Jain S, Becerra L, Ganiats T
UC San Diego, La Jolla, CA, USA

URINARY/KIDNEY

Clinical Outcomes Studies

PUK1
A RETROSPECTIVE COMPARATIVE ANALYSIS OF TREATMENT OUTCOMES OF ALPHA-BLOCKERS IN THE MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA WITHIN A MANAGED CARE POPULATION
Pandya A1, Thompson D1, McGarry L1, Sander S2, Shah H2
1i3 Innovus, Medford, MA, USA, 2Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA

PUK2
OUTCOMES AND COSTS ASSOCIATED WITH IMMUNOSUPPRESSION COMPLIANCE
Takemoto SK1, Pinsky B1, Woodward RS2
1Saint Louis University, Saint Louis, MO, USA, 2University of New Hampshire, Durham, NH, USA

PUK3
RISK FACTORS ASSOCIATED WITH MEDICATION NONADHERENCE AMONG RENAL TRANSPLANT RECIPIENTS
Kwong WJ1, Chisholm MA2, Spivey CA2
1University of Georgia, Athens, GA, USA, 2University of Georgia, Augusta, GA, USA

PUK4
HAEMOGLOBIN FLUCTUATIONS IN HAEMODIALYSIS PATIENTS RECEIVING INTRAVENOUS EPOETIN ALFA OR INTRAVENOUS DARBEPOETIN ALFA
Walker R1, Pussell BA2
1Royal Melbourne Hospital, Parkville, VIC, Australia, 2Prince of Wales Hospital, Randwick, NSW, Australia

PUK5
FLUCTUATIONS IN HAEMOGLOBIN LEVELS IN PREDIALYSIS AND PERITONEAL DIALYSIS PATIENTS RECEIVING INTRAVENOUS EPOETIN ALFA OR INTRAVENOUS DARBEPOETIN ALFA
Walker R1, Pussell BA2
1Royal Melbourne Hospital, Parkville, VIC, Australia, 2Prince of Wales Hospital, Randwick, NSW, Australia

Cost Studies

PUK6
IMPACT OF AN INCREMENTAL INCREASE IN PERITONEAL DIALYSIS UTILIZATION ON HOSPITAL BUDGETS IN COLOMBIA: USE OF A BUDGET IMPACT MODEL
Walker DR1, Sanabria M2, Bhattacharyya SK1, Astudillo K2, Diaz FJ2, Camargo D2, Enriquez J2, Blackburn JC3
1Baxter Health Care, McGaw Park, IL, USA, 2Baxter Colombia, Bogota, Cundinamarca, Colombia, 3Baxter Export Corporation, Fort Lauderdale, FL, USA

PUK7
GENERIC SUBSTITUTION OF TACROLIMUS AFTER RENAL TRANSPLANTATION: A DECISION-MAKING MODEL TO WEIGH RISKS AND BENEFITS
Fonseca M1, Duchesne I2, Bacaltchuk J2, Araujo G1
1Axia.Bio Consulting, São Paulo, Brazil, 2Janssen-Cilag, Sao Paulo, Brazil

PUK8
COST EFFECTIVENESS OF ICODEXTRINE-BASED SOLUTIONS IN END STAGE RENAL DISEASE PATIENTS UNDERGOING PERITONEAL DIALYSIS THERAPY
Garcia-Contreras F1, Constantino-Casas P1, Prieto-Arenas I2, Amato D3, Blackburn JC4, Bhattacharyya SK5, Paniagua-Sierra R3
1Mexican Institute of Social Security, México, Distrito Federal, Mexico, 2BAXTER MEXICO, Mexico, DF, Mexico, 3National Medical Center XXI Century, Mexico, DF, Mexico, 4Baxter Export Corporation, Fort Lauderdale, FL, USA, 5Baxter Health Care, McGaw Park, IL, USA

PUK9
A RETROSPECTIVE MATCHED COHORT STUDY OF THE BURDEN OF SECONDARY HYPERPARATHYROIDISM (SHPT) IN PREDIALYSIS PATIENTS WITHOUT VITAMIN D RECEPTOR (VDR) ACTIVATOR THERAPY
Marx S1, Kalantar-Zadeh K2, Schumock GT3, Melnick JZ4, Sterz R5, Joyce AT6, Smith PJ7, Sacks NC8, Blakesley VA4
1Abbott Laboratories, Abbott Park, IL, USA, 2Harbor-UCLA Medical Center, Torrance, CA, USA, 3University of Illinois at Chicago, Chicago, IL, USA, 4Abbott, Abbott Park, IL, USA, 5Abbott GmbH & Co. KG, Ludwigshafen, -, Germany, 6Pharmetrics, Inc, Watertown, MA, USA, 7PharMetrics, a unit of IMS, Watertown, MA, USA, 8PharMetrics, Inc., a unit of IMS, Waretown, MA, USA

PUK10
COST ANALYSIS OF PRE-DIALYSIS CHRONIC KIDNEY DISEASE: AN EMPLOYER'S PERSPECTIVE
Moyneur É1, Bookhart B2, Mody S2, Fournier AA1, Mallett D3, Duh M4
1Groupe d'Analyse, Inc, Montréal, QC, Canada, 2Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA, 3Ingenix Employer Solutions, New Haven, CT, USA, 4Analysis Group, Inc, Boston, MA, USA

PUK11
MEDICAL AND WORK PRODUCTIVITY COSTS BEFORE AND AFTER DIAGNOSIS OF ANEMIA IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) PATIENTS
Moyneur É1, Bookhart B2, Mody S2, Guérin A3, Mallett D4, Piech CT2, Duh MS5
1Groupe d'Analyse, Inc, Montréal, QC, Canada, 2Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA, 3Groupe d'Analyse, Ltée, Montréal, QC, Canada, 4Ingenix Employer Solutions, New Haven, CT, USA, 5Analysis Group, Inc, Boston, MA, USA

PUK12
THE COST-EFFECTIVENESS OF MYCOPHENOLATE MOFETIL (MMF) AS FIRST-LINE THERAPY IN ACTIVE LUPUS NEPHRITIS
Wilson EC1, Jayne DR2, Dellow E3, Fordham RJ1
1University of East Anglia, Norwich, Norfolk, UK, 2University of Cambridge, Cambridge, Cambs, UK, 3Aspreva Pharmaceuticals Ltd, Bagshot, Surrey, UK

PUK13
PANEL DATA ANALYSIS SHOWS PERITONEAL DIALYSIS TO BE NEGATIVELY ASSOCIATED WITH HOSPITALIZATION AT THE STATE LEVEL
Walker DR, DuChane J, Bhattacharyya SK
Baxter Health Care, McGaw Park, IL, USA

Health Care Use & Policy Studies

PUK14
ANEMIA-RELATED TREATMENT VARIATIONS IN WOMEN WITH CHRONIC KIDNEY DISEASE IN US OUTPATIENT SETTINGS
Rasu RS1, Balkrishnan R2
1University of Missouri Kansas City, Kansas City, MO, USA, 2The Ohio State University College of Pharmacy, Columbus, OH, USA

PUK15
DRUG UTILIZATION AND COSTS OF ERYTHROPOIETIC AGENTS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE
Lefebvre P1, Duh MS2, Laliberte F1, Mckenzie RS3, Mody S3, Bookhart B3, Piech CT3
1Groupe d'Analyse, Ltée, Montréal, QC, Canada, 2Analysis Group, Inc, Boston, MA, USA, 3Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA

Patient-Reported Outcomes

PUK16
ASSESSMENT OF ADHERENCE WITH IMMUNOSUPPRESSANT MEDICATIONS IN TRANSPLANT PATIENTS AND THE POTENTIAL COST SAVINGS ASSOCIATED WITH INCREASED ADHERENCE
Harpe SE1, Matzke GR1, Osbon C2, Ranade D3, Barrett T2, Kaplan T4, Mantell B5, Skelton H6
1Virginia Commonwealth University, Richmond, VA, USA, 2Transcript Pharmacy, Inc, Jackson, MS, USA, 3Skyemed Pharmacy, Pompano Beach, FL, USA, 4Amber Pharmacy, Omaha, NE, USA, 5Echo Drugs, Flushing, NY, USA, 6F&M Specialty Pharmacy, Jackson, MS, USA

PUK17
STRESS URINARY INCONTINENCE: EFFECT OF OBESITY IN PATIENTS' PERCEPTION OF HEALTH RELATED QUALITY OF LIFE
Fonseca ESM, Moreno AL, Fonseca MCM, Castro RA, Sartori MGF, Girão MJBC
UNIFESP – Federal University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil

PUK18
LINGUISTIC VALIDATION OF THE NOCTURIA QUALITY OF LIFE (N-QOL) QUESTIONNAIRE IN 10 LANGUAGES
Vats V1, McKown S2, Gawlicki M3
1Pfizer, Inc, New York, NY, USA, 2Corporate Translations, Inc, Chicago, IL, USA, 3Corporate Translations, Inc, East Hartford, CT, USA

PUK19
LINGUISTIC VALIDATION OF THE ICIQ MALE SEXUAL MATTERS ASSOCIATED WITH LOWER URINARY TRACT SYMPTOMS QUESTIONNAIRE (ICIQ-MLUTSSEX) IN 7 LANGUAGES
Vats V1, McKown S2, Gawlicki M3
1Pfizer, Inc, New York, NY, USA, 2Corporate Translations, Inc, Chicago, IL, USA, 3Corporate Translations, Inc, East Hartford, CT, USA

PUK20
IMPACT OF SOLIFENACIN ON QUALITY OF LIFE, MEDICAL CARE USE, WORK PRODUCTIVITY, AND HEALTH UTILITY IN THE ELDERLY
Noe L1, Marshall TS2, Rasouliyan L3, Runken MC4, Zinner NR5
1Ovation Research Group, Highland Park, IL, USA, 2Astellas Pharma US, Deerfield, IL, USA, 3Ovation Research Group, San Francisco, CA, USA, 4GlaxoSmithKline, Research Triangle Park, NC, USA, 5Western Clinical Research, Inc, Torrance, CA, USA


12th Annual International Meeting Main Page